A HEPCIDIN INHIBITOR MOBILIZES IRON FOR INCORPORATION INTO RED BLOOD CELLS IN AN ADENINE-INDUCED KIDNEY DISEASE MODEL IN RATS by V. Vaja
 University of Milan 
Doctoral School in Molecular Medicine 
 
 
A HEPCIDIN INHIBITOR MOBILIZES IRON FOR 
INCORPORATION INTO RED BLOOD CELLS IN AN 
ADENINE-INDUCED KIDNEY DISEASE MODEL IN RATS  
 
PHD STUDENT: Valentina Vaja 
 
TUTOR: Professor Maria Domenica Cappellini 
CO-TUTOR: Doctor Jodie Babitt 
 
 
PHD SCHOOL DIRECTOR: Professor Mario Clerici 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
i 
 
ABSTRACT 
 
Anemia is prevalent in patients with chronic kidney disease (CKD) and is primarily 
due to a complex interplay of relative erythropoietin deficiency, shortened red blood 
cell survival and abnormalities in iron homeostasis. A key feature in many patients 
with anemia of CKD is the limited iron availability for an efficient erythropoiesis 
despite adequate body iron stores. It is now well established that excess levels of 
the iron regulatory hormone hepcidin are responsible for downregulating the 
functional expression of the cellular iron exporter, ferroportin, thereby resulting in a 
blockade of iron absorption from the diet and iron retention in reticuloendothelial 
macrophage stores.  
Adenine treatment in rats has been proposed as an animal model of anemia of 
CKD with high hepcidin levels that mirrors the condition in patients. 
We developed a adenine-induced renal failure model in rats that simulates the 
renal failure and anemia condition in patients. We modified the Yokozawa et al. 
model by giving a diet supplemented with 0.75% adenine for 3 weeks followed by 
adenine free normal diet for another 3 weeks.  
We then tested whether the small molecule bone morphogenetic protein (BMP) 
inhibitor LDN-193189, which has previously been shown to lower hepcidin levels, 
was able to mobilize iron into the plasma and improve iron-restricted erythropoiesis 
in adenine-treated rats. 
The modified adenine model had a higher survival rate than previously reported 
models, while maintaining irreversible renal failure and anemia. We demonstrated 
that adenine rats had increased hepatic hepcidin mRNA levels, decreased serum 
iron concentration, increased spleen iron content, low hemoglobin levels and 
inappropriately low EPO levels relative to the degree of anemia, typical of the 
clinical condition in patients with anemia of CKD.  
LDN-193189 lowered hepatic hepcidin mRNA and mobilized stored iron into 
plasma in adenine-treated rats. Moreover, the iron was efficiently incorporated into 
hemoglobin in reticulocytes. However, LDN-193189 alone did not prevent anemia 
progression in our model.  
Lowering hepcidin improved iron availability, but did not improve anemia in an 
adenine-induced kidney disease model in rats. Co-administration of hepcidin 
lowering agents with erythropoiesis stimulating agents (ESAs) may be useful as a 
combination therapy to correct iron balance and thereby reduce the ESA dose 
needed to achieve target hemoglobin levels.  
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RIASSUNTO 
 
L’anemia da insufficienza renale cronica è la conseguenza sia di una ridotta 
produzione di globuli rossi a livello del midollo osseo che di una minore 
sopravvivenza degli stessi e di una conseguente alterazione dell’omeostasi del 
ferro. L’eritropoiesi inefficace è prevalentemente correlata al deficit della sintesi 
dell’eritropoietina,  ormone prodotto dal rene che stimola a livello del midollo osseo 
la produzione di globuli rossi. Una caratteristica fondamentale di molti pazienti con 
anemia da insufficienza renale cronica è la limitata disponibilità di ferro per 
un’efficiente eritropoiesi nonostante vi siano adeguati depositi di ferro 
nell'organismo.  E’ ormai ben noto che alti livelli di epcidina, il principale ormone 
regolatore dell’omeostasi del ferro, sono responsabili della down-regolazione 
dell'espressione funzionale della ferroportina, unico esportatore cellulare di ferro, 
che provoca un blocco dell’ assorbimento di ferro dalla dieta e l’accumulo di ferro 
nei macrofagi reticoloendoteliali. Il principale pathway di regolazione 
dell’espressione dell’epcidina è la via delle BMPs (Bone Morphogenetic Proteins), 
che attraverso la fosforilazione e la conseguente attivazione delle proteine SMAD, 
attiva il promotore dell’epcidina e ne induce quindi la sintesi. 
Un modello animale di anemia da insufficienza renale con un quadro che 
rispecchia la condizione clinica di pazienti caratterizzata da elevati livelli di epcidina 
è quello che prevede l’utilizzo di ratti con danni renali indotti da una dieta ricca di 
adenina. 
In questo studio e’ stato sviluppato un modello animale da insufficienza renale, che 
simula la condizione di insufficienza renale e anemia nei pazienti, modificando il 
modello di Yokozawa. E’ stato poi testato se l’inibitore delle BMPs, LDN-193189, 
fosse in grado di mobilizzare il ferro e migliorare l'eritropoiesi nel modello animale. 
Questa molecola è nota per essere in grado di inibire in modo specifico la via di 
stimolazione BMP-dipendente interagendo con il recettore a livello extracellulare. 
Il modello animale ha presentato un tasso di sopravvivenza più elevato rispetto ai 
modelli precedentemente riportati, pur mantenendo un’ irreversibile insufficienza 
renale e una grave anemia. I ratti hanno presentato elevati livelli di epcidina 
epatica, diminuzione della concentrazione sierica di ferro, maggiore contenuto di 
ferro nella milza, bassi livelli di emoglobina e livelli impropriamente bassi di EPO 
rispetto al grado di anemia, tipica condizione clinica che si evidenzia in pazienti con 
anemia da insufficienza renale cronica.  
Il trattamento con LDN-193189 ha indotto l’inibizione dell’espressione epatica di 
epcidina, attraverso il blocco della via BMPs, ed ha indotto una mobilizzazione del 
ferro accumulato con un suo riversamento nel plasma. Inoltre, il ferro è stato 
incorporato in modo efficiente nell’emoglobina dei reticolociti. Tuttavia, il composto 
da solo non ha impedito la progressione dell’anemia nel modello animale proposto. 
La diminuzione dei valori di epcidina ha portato ad un conseguente incremento di 
ferro disponibile, ma non ha permesso il miglioramento dell'anemia.  
La co-somministrazione di agenti in grado di diminuire i livelli di epcidina e agenti 
stimolanti l'eritropoiesi (ESA) potrebbe essere un’utile terapia di combinazione per 
correggere l'equilibrio di ferro e, quindi, ridurre la dose di ESA necessario per 
raggiungere i livelli di emoglobina target. 
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1. INTRODUCTION 
 
1.1 Anemia of CKD 
 
Chronic kidney disease (CKD) affects approximately 26 million adults in the United 
Sates and millions of others are at risk (1). CKD is associated with significant 
morbidity and mortality, and these patients face many other medical problems 
related to CKD. One of the major medical issues facing this population is anemia, 
which often develops early in the course of CKD and contributes to poor quality of 
life. It has been shown to be strongly predictive of adverse effects, including 
complications and death from cardiovascular causes.(2) Prior to the availability of 
human recombinant erythropoietin, patients receiving chronic dialysis treatment 
frequently required blood transfusions, exposing them to iron overload, viral 
hepatitis and HIV, and increasing production of antibodies to human antigens 
which can severely limit transplantation options. 
The introduction of recombinant human erythropoietin in the late 1980s drastically 
changed the treatment of anemia in patients with CKD. The benefits of anemia 
treatment in this population reach far beyond the improvement of fatigue and 
decreased physical activity to a broad spectrum of physiologic functions. Thus the 
presence of anemia should be sought, diagnosed, and treated early in patients with 
CKD. The optimal hemoglobin (Hb) targets are still controversial and studies 
defining these goals are ongoing. The costs of anemia management in the chronic 
kidney disease population are considerable and need to be considered along with 
the risks and benefits. 
 
1.1.1. Pathophysiology of anemia in patients with CKD 
 
Anemia is defined by the World Health Organization as a Hb concentration less 
than 13.0 g/dL in adult males and non-menstruating females and less than 12.0 
g/dL in menstruating females.(3) Anemia is a common problem in patients with 
CKD, and its incidence increases as glomerular filtration rate declines. Population 
studies such as the National Health and Nutrition Examination Survey (NHANES) 
by the National Institutes of Health and the Prevalence of Anemia in Early Renal 
Insufficiency (PAERI) study suggest that the incidence of anemia is less than 10% 
in CKD stages 1 and 2, 20–40% in CKD stage 3, 50–60% in CKD stage 4 and 
more than 70% in CKD stage 5 (4,5). 
The cause of anemia in patients with CKD is multifactorial. The most well-known 
cause is inadequate erythropoietin (EPO) production, which is often compounded 
by iron deficiency. As renal failure progresses, the contribution of EPO deficiency 
to anemia increases. The role of decreased renal EPO synthesis in CKD-
associated anemia is supported by the severe anemia seen in anephric patients 
(6). However, the mechanisms impairing renal EPO production are not well 
understood. The production capacity of EPO remains significant even in end stage 
renal disease (ESRD) as these patients have been shown to respond with 
increased EPO synthesis in the setting of an additional hypoxic stimulus.(7) This 
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suggests that the decrease in EPO production in CKD is, in part, a physiologic 
response to achieve a chronically reduced Hb concentration. 
Typically, EPO is produced in the peritubular capillary endothelial cells in the 
kidney relying on a feedback mechanism measuring total oxygen carrying capacity. 
Hypoxia inducible factor (HIF), which is produced in the kidney and other tissues, is 
a substance whose spontaneous degradation is inhibited in the presence of 
decreased oxygen delivery due to anemia or hypoxemia. The continued presence 
of HIF leads to signal transduction and the synthesis of EPO. Therefore the usual 
response is increased EPO production in the setting of anemia. The EPO then 
binds to receptors on erythroid progenitor cells in the bone marrow, specifically the 
burst-forming units (BFU-E) and colony-forming units (CFU-E). With EPO present, 
these erythroid progenitors differentiate into reticulocytes and red blood cells 
(RBCs). The absence of EPO leads to pre-programmed apoptosis. This is 
mediated by the Fas antigen. The decreased red blood cell production and 
continued loss of blood (by programmed red blood cell death) leads to worsening 
anemia. 
There are other factors in chronic kidney disease which contribute to anemia. 
Acute and chronic inflammatory conditions have a significant impact on anemia in 
the CKD population by proinflammatory cytokines decreasing EPO production and 
inducing apoptosis in colony-forming unit-erythroid cells (CFU-E). The early 
induction of apoptosis in CFU-E cells stops the process of development into RBC. 
Inflammatory cytokines have also been found to induce the production of hepcidin, 
a recently discovered peptide generated in the liver, which interferes with RBC 
production by decreasing iron availability for incorporation into erythroblasts. This 
also impairs the production of RBC. Figure 1 illustrates the above-mentioned 
interactions. 
Red blood cells also have a decreased life span in patients with CKD. While the 
normal life span of an RBC is about 120 days, it has been demonstrated that this is 
shortened to only 60–90 days in CKD patients. In patients without CKD, the bone 
marrow has significant capacity to increase red blood cell production and to correct 
for the shortened life span, but this response is blunted in patients with CKD by the 
relative EPO deficiency. Uremic toxins have been implicated as contributing to 
apoptosis as the anemia will often improve after initiation of dialysis. There have 
been a number of prospective and observational studies that have demonstrated 
improved Hb levels and decreased dose of erythropoiesis-stimulating agents 
(ESAs) with increased adequacy of dialysis (8-11).  
It has been hypothesized that it is the middle molecules (molecular weight range of 
500–2000 daltons) of uremia that contribute to bone marrow suppression (12). 
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Fig. 1. Erythropoiesis in chronic kidney disease. Ag, antigen; EPO, erythropoietin; 
Fe, iron; IFN, interferon; IL, interleukin; RBCs, red blood cells; TNF, tumor necrosis 
factor. 
 
Inadequate production of erythropoietin commonly is believed to be the most 
important factor in the pathogenesis of anemia in these patients, and many 
patients are treated with ESAs. However, approximately 10%-20% of patients are 
poorly responsive to ESA therapy (13). Prospective randomized controlled clinical 
trials, including the US Normal Hematocrit Study and the CHOIR (Correction of 
Hemoglobin and Outcomes in Renal Insufficiency) Study, raised concerns about 
the safety of ESAs when dosed to target higher hemoglobin levels, particularly 
when using higher doses and in patients who are poorly responsive to therapy (14-
16). This has resulted in a US Food and Drug Administration black box warning on 
the product labeling of ESAs and significant controversy about the management of 
anemia in patients with CKD. 
The cause of anemia in patients with CKD is multifactorial. In addition to relative 
erythropoietin deficiency, shortened erythrocyte survival and the erythropoiesis-
inhibitory effects of accumulating uremic toxins also contribute to the anemia of 
CKD.  Importantly, patients with CKD also have several abnormalities in systemic 
homeostasis of iron, an essential component in the production of red blood cells 
(17-18). First, hemodialysis patients in particular typically are in negative iron 
balance, losing approximately 1-3 g of iron per year, caused in part by blood 
trapping in the dialysis apparatus and repeated phlebotomy. Second, many 
patients are on ESA therapy to manage their anemia, which depletes iron stores by 
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driving increased production of red blood cells. Third, it has been recognized that 
patients with CKD also have impaired absorption of dietary iron. Randomized 
controlled trials have shown that oral iron is no better than placebo to treat iron 
deficiency in patients on hemodialysis therapy (19-21). These abnormalities of iron 
metabolism in patients with CKD may result in true iron deficiency, manifest as low 
serum transferrin saturation and ferritin level, which can be treated with 
supplemental iron. However, many patients also have a functional iron deficiency 
or reticuloendothelial cell iron blockade, characterized by low levels of circulating 
iron that limit erythropoiesis, even in the face of adequate or increased body iron 
stores. Management of these patients is less clear. This reticuloendothelial cell iron 
sequestration is characteristic of anemia of inflammation (also known as anemia of 
chronic disease), seen not only in patients with CKD, but also in patients with many 
other chronic diseases, including autoimmune disorders, chronic infections, and 
malignancy. Many patients with CKD have a chronic inflammatory state, which may 
be caused by an increased incidence of infections and/or induction of inflammatory 
cytokines by the hemodialysis procedure (22). Recent research suggests that the 
impaired intestinal iron absorption and impaired release of iron from body stores in 
patients with CKD, as in other patients with anemia of inflammation, may be 
caused by an excess of the key iron regulatory hormone hepcidin (23-25). 
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1.2 Iron biology and homeostasis  
 
1.2.1 Iron Intake 
 
Iron is the most abundant element on Earth by mass and the fourth most abundant 
in the Earth’s crust but it readily oxidizes into insoluble compounds with poor 
bioavailability. In this environment, biological organisms evolved to conserve iron. 
Quantitative analysis of tissue iron distribution and fluxes in humans illustrates how 
this is accomplished (26). 
The typical adult human male contains about 4 g of iron of which about 2.5 g is in 
hemoglobin, 1 g is stored predominantly in hepatocytes and hepatic and splenic 
macrophages, and most of the rest is distributed in myoglobin, cytochromes, and 
other ferroproteins. Only about 1–2 mg/day is lost from the body predominantly 
through desquamation and minor blood loss. In the steady state, this amount is 
replaced through intestinal iron absorption. Although the loss of iron may increase 
slightly with increasing iron stores, these changes do not significantly contribute to 
homeostasis; intestinal iron absorption is by far the predominant determinant of the 
iron content of the body. 
Recovery from blood loss causes an increase in iron absorption up to 20-fold, 
indicating that the duodenum where iron absorption takes place has a large 
reserve capacity for iron absorption. 
 
1.2.2 Iron Recycling 
 
Under normal circumstances, the reutilization of iron recycled from senescent cells 
accounts for most of the iron flux in humans. With the erythrocyte lifespan of 120 
day, 20 – 25 mg of iron is required to replace the 20 – 25 mL of erythrocytes that 
must be produced every day to maintain a steady state. Other cell types also turn 
over but their much lower iron content contributes relatively little to the iron flux. 
Macrophages in the liver, spleen, and marrow (formerly called the 
reticuloendothelial system) phagocytose senescent or damaged erythrocytes, 
degrade their hemoglobin to release heme, extract iron from heme using heme 
oxygenase (27) and recycle the iron to the extracellular fluid and plasma. Steady-
state iron flux from recycling can increase up to 150 mg/d in conditions with 
ineffective erythropoiesis in which the number of erythroid precursors is increased 
and accompanied by the apoptosis of hemoglobinized erythrocyte precursors in the 
marrow and shortened erythrocyte survival (28). 
 
1.2.3 Iron Distribution and Storage 
 
Free iron is highly reactive and causes cell and tissue injury through its ability to 
catalyze the production of reactive oxygen species. In living organisms, iron is 
complexed with proteins or small organic molecules (citrate, acetate), which 
mitigate its reactivity. Transferrin is the physiological carrier of iron in plasma. 
Normally, only 20% – 40% of the available binding sites on transferrin molecules 
are occupied by ferric iron. The iron content of plasma is only 2 – 3 mg so this 
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compartment must turn over every few hours. Erythrocyte precursors take up iron 
almost exclusively through transferrin receptors (TfR1) so the iron supply to 
erythrocyte precursors is completely dependent on plasma transferrin. In contrast, 
hepatocytes and other non-erythroid cells can also take up iron that is not bound to 
transferrin (nontransferrin-bound iron or NTBI), a process that becomes important 
during iron overload when plasma transferrin saturation reaches 100% (29). The 
predominant cellular storage form of iron is the hollow spherical protein ferritin 
whose cavity contains iron in ferric form complexed with hydroxide and phosphate 
anions. 
 
1.2.4 Regulation of Plasma Iron Concentrations 
 
Despite varying dietary iron intake and changes in erythropoietic activity owing to 
occasional or periodic blood loss, iron concentrations in plasma normally remain in 
the 10 – 30 mM range. Chronically low concentrations decrease iron supply to 
erythropoiesis and other processes leading to anemia and dysfunction of other cell 
types sensitive to iron deprivation. Chronically high iron concentrations lead to 
intermittent or steady-state saturation of transferrin with iron and the generation of 
NTBI with consequent deposition of excess iron in the liver, endocrine glands, 
cardiac myocytes, and other tissues. Excess cellular iron may cause tissue injury 
by catalyzing the generation of reactive oxygen species, which can cause DNA 
damage, lipid peroxidation, and oxidation of proteins. 
 
1.2.5 Systemic Iron Homeostasis 
 
Phenomenological description of systemic iron homeostasis was developed 
starting in the 1930s (26). Homeostatic mechanisms regulate dietary iron 
absorption and iron deposition into or withdrawal from stores depending on the 
amount of stored iron (“stores regulator”) and the requirements of erythropoiesis 
(“erythropoietic regulator”). The description of the molecular processes that 
underlie iron homeostasis has progressed rapidly in the last two decades but is still 
not complete. 
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1.3 Cellular iron regulation  
 
1.3.1 Cellular Iron 
 
Cells require iron predominantly for incorporation into various ferroproteins, where 
iron exists in iron – sulfur clusters, in heme or hemelike prosthetic moieties, or in 
other more loosely associated forms. It now appears that most cell types in the 
body autonomously regulate their iron uptake solely to meet their individual 
requirements for iron. These cells do not export appreciable amounts of iron and 
are presumed to give up their iron only when they undergo cell death and are 
recycled by macrophages. In contrast, several specialized cell types supply or 
store iron to meet the needs of the entire organism, and are therefore equipped to 
export iron into extracellular fluid and plasma. Iron-exporting cells include duodenal 
enterocytes that absorb dietary iron, macrophages that recycle iron from senescent 
or dead cells, and macrophages and hepatocytes that store iron and release it to 
meet systemic demand. During pregnancy, the placental syncytiotrophoblast must 
transport maternal iron into the fetal circulation to meet the iron requirements of 
fetal growth and development. The endothelial cells that form the blood – brain 
barrier must also selectively transport iron as it now appears that the iron 
concentrations in the brain are not appreciably increased in systemic iron overload 
disorders. Finally, erythroid precursors need much more iron than any other cell 
type as each cell synthesizes more than a billion heme molecules, therefore facing 
greater iron-homeostatic challenges. 
 
1.3.2 Cellular Iron Uptake 
 
Transferrin-mediated iron uptake is the best understood mechanism of cellular iron 
import. Although the transferrin receptor (TfR1) is expressed in many cell types, 
erythrocyte precursors contain most of the TfR1 molecules and take up the great 
majority of iron-transferrin in the organism. Iron-transferrin is endocytosed via the 
cell membrane TfR1 and internalized into endosomal recycling vesicles. As the 
vesicle acidifies, the low pH releases the transferrin- bound ferric iron and the iron-
free (apo)transferrin-TfR1 complex returns to the cell membrane (Fig. 2) 
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Fig. 2. Iron traffic in erythrocyte precursors synthesizing hemoglobin. Iron is taken 
up as diferric transferrin by the transferrin receptor (TfR1). Acidification of the 
endocytic vesicle releases ferric iron from transferrin, and the membrane 
ferrireductase Steap3 reduces it to ferrous iron, which is then exported to the 
cytoplasm by DMT1. The complex of iron-free apotransferrin (Tf ) and TfR1 is 
returned to the plasma membrane where the neutral pH causes Tf to dissociate 
from its receptor. The transferrin cycle is completed when Tf is reloaded with ferric 
iron by duodenal enterocytes or iron-recycling macrophages. Ferrous iron exported 
by DMT1 may be delivered to mitochondrial mitoferrin-1 (Mfrn1) by direct contact 
(the kiss-and-run mechanism, K&R) or through intermediate transport by as-yet 
uncharacterized cytoplasmic chaperones (Fe2þCh). Mitoferrin-1 imports iron into 
mitochondria where iron is incorporated into newly synthesized heme. Heme is 
exported via an unknown exporter (Heme export) and incorporated into globin 
chains to generate hemoglobin. Under some circumstances, iron is exported as 
ferrous iron via ferroportin (Fpn) or as heme via feline leukemia virus C receptor 
(FLVCR1). 
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The neutral pH at the membrane causes the apotransferrin to dissociate from TfR1, 
whereupon apotransferrin diffuses away to be loaded with iron again, repeating the 
cycle. From the vesicle, iron is delivered to mitochondria where it is incorporated 
into protoporphyrin IX to form heme, or incorporated into nascent iron – sulfur 
clusters. Alternatively, iron can be exported from the vesicle into the cytoplasm 
where it is incorporated into cytoplasmic ferroproteins or stored in cytoplasmic 
ferritin. 
Nontransferrin-bound iron (NTBI) (29) usually accumulates when the iron- binding 
capacity of transferrin is exceeded and then circulates complexed mostly with 
citrate or acetate. Hemoglobinopathies such as -thalassemia major and 
intermedia are associated with particularly high levels of NTBI. Some cells, 
including hepatocytes, cardiomyocytes, and cells of endocrine glands can take up 
NTBI, although the precise mechanism is not well understood. Candidate NTBI 
transporters include L-type voltage-gated calcium channels, DMT-1 and Zip14. 
 
1.3.3 Intracellular Iron Transport 
 
To undergo transport to the cytoplasm or mitochondria, ferric iron must be reduced 
to its ferrous form through the action of ferrireductases. Recent studies indicate 
that Steap (sixtransmembrane epithelial antigen of the prostate) proteins 1 – 4 are 
among the relevant ferrireductases, with Steap3 having a particular importance in 
erythroid precursors (Fig. 2), assisted perhaps by Steap2 and Steap4 (30). To 
reach the cytoplasm, ferrous iron must cross the membrane of the vesicle. In many 
cells, the proton-dependent ferrous iron transporter divalent metal transporter-1 
(DMT1) appears essential for iron transport from the vacuole into the cytoplasm but 
in macrophages its homolog natural resistance-associated macrophage protein 
(Nramp1) may also contribute (31). Because of its chemical reactivity, iron is 
chaperoned in the cytoplasm, at least in part by multifunctional poly(RC)- binding 
proteins (PCBPs) (32). In particular, PCBP1 mediates the delivery of iron to 
cytoplasmic ferritin and both PCBP1 and 2 are involved in the delivery of iron to 
cytoplasmic iron-dependent prolyl and asparaginyl hydroxylases that mediate 
oxygen sensing (33). It is not known how iron is transported to mitochondria. In 
erythroid cells, there is evidence for a “kiss-and-run” mechanism (Fig. 2) whereby 
iron could be transferred from endosomal vesicles directly to mitochondria (34) but 
it is not clear how much this mechanism contributes to the iron flux into 
mitochondria and whether it also functions in nonerythroid cell types. 
 
1.3.4 Mitochondria and Iron 
 
Consistent with their autonomous evolutionary origin, mitochondria are equipped 
with distinct iron transporters. Iron uptake into mitochondria depends on the inner 
mitochondrial membrane proteins mitoferrin 1 and 2, with the former predominantly 
expressed in erythroid cells and the latter ubiquitously (35). In erythroid cells, 
mitoferrin 1 interacts with the ATP-binding transporter Abcb10 and with 
ferrochelatase to form a plausible pathway for the delivery of iron for heme 
formation (36). How heme is exported from mitochondria for incorporation into 
10 
 
hemoglobin and other hemoproteins is not known. Mitochondria also contain a 
distinct ferritin, mitochondrial ferritin, for local iron storage. 
 
1.3.5 Cellular Iron Homeostasis 
 
Cellular, as opposed to systemic, iron homeostasis assures that sufficient but not 
excessive amounts of iron are taken up by each cell to meet its individual 
requirement for ferroprotein synthesis. The system that has evolved relies on 
posttranscriptional regulation through the interaction of iron-regulatory proteins 
(IRP1 and IRP2) with iron-regulatory elements (IREs) in messenger RNAs 
(mRNAs) that encode key iron transporters, ferroproteins, and enzymes involved in 
iron-utilizing pathways. The IRE/ IRP system effectively regulates iron uptake, 
provides for the storage of excess iron in ferritin, and coordinates the synthesis of 
heme, iron – sulfur clusters, and ferroproteins with the availability of iron. The 
system in effect acts to decrease wasted expenditure of synthetic energy and 
substrates, and to prevent accumulation of toxic forms of iron. Target mRNAs 
contain IREs that form characteristic stem-loop structures either in the 50 region, 
where IRP binding represses translation and decreases protein synthesis, or in the 
30 region where IRP binding prevents endonucleases from cleaving sensitive 
regions of the mRNA, thus stabilizing mRNA and increasing protein synthesis (37). 
IRP1 and IRP2 are structurally related but interact with iron in distinct ways. Both 
proteins bind to IREs when cellular iron levels are low. In the presence of iron, 
IRP1 incorporates an iron–sulfur cluster, does not bind IREs, and acts as an 
aconitase enzyme converting citrate to isocitrate in the Krebs cycle. In contrast, 
IRP2 is ubiquitinated by a complex iron-dependent process and then degraded in 
proteasomes (38,39). The dual specificity of IRP1/aconitase may have a functional 
role in the regulation of erythropoiesis by iron availability, as the provision of the 
aconitase product isocitrate reverses some of the suppressive effect of iron 
deprivation on erythropoiesis and the enzymatic inhibition of aconitase has the 
opposite effect (40,41). Many mRNAs are regulated by the IRP/IRE system (42) 
and fall into three classes: (1) iron acquisition, generally with IREs in the 30 region 
resulting in increased protein synthesis during cellular iron deprivation; (2) iron 
utilization and storage, with IREs in the 50 region, resulting in repressed protein 
synthesis during iron deprivation; and (3) iron export, with IREs also in the 50 
region and protein synthesis repressed during iron deprivation. Proteins subject to 
IRE/IRP regulation include TfR1 and DMT1 involved in cellular iron uptake, 
aminolevulinic acid synthase 2, which catalyzes the first step of the heme synthesis 
pathway in erythroid cells, the heavy and light subunits of ferritin involved in iron 
storage, and ferroportin, the iron exporter expressed in tissues and cells involved in 
iron export to plasma. The net effect of the IRE/IRP response during cellular iron 
deficiency is to increase cellular iron uptake, mobilize iron from cellular storage, 
decrease iron utilization, and, when iron becomes sufficient or excessive to reverse 
these responses and direct more iron into cellular storage and export. Further fine-
tuning of iron import and export is achieved by differential splicing of target mRNAs 
in different tissues to either include or exclude IREs. As an example, systemic 
adaptation to iron deficiency may be facilitated by a ferroportin mRNA isoform that 
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lacks IRE, which may allow iron-transporting duodenal enterocytes to deliver iron to 
plasma for systemic needs even if the enterocyte is sensing iron deficiency, and 
may transfer iron from erythroid cells to other tissues more critically dependent on 
iron (43). 
 
1.3.6 Generalized Regulation of Protein Synthesis by Iron in Erythroid 
Cells 
 
In addition to the regulation of the synthesis of individual proteins by iron, erythroid 
cells also contain a mechanism for a generalized adaptive response to iron 
deficiency. This response is affected by the heme-regulated inhibitor kinase (HRI) 
belonging to a class of kinases activated by cellular stress, including nutrient 
deprivation, viral infection, and endoplasmic reticulum stress (44). During iron 
deficiency as heme concentrations drop, heme dissociates from HRI, causing it to 
undergo specific autophosphorylation to become a catalytically active kinase 
targeting the a subunit of eukaryotic translational initiation factor 2 (eIF2a). 
Activated HRI inhibits translational initiation by phoshorylating eIF2a. Not all protein 
synthesis is inhibited however, as activated HRI may promote the synthesis of 
transcription factors that are protective during iron-deficient erythropoiesis (45). A 
priori, it is not obvious how iron deficiency results in the production of smaller, less-
hemoglobinized erythrocytes rather than fewer normally sized and hemoglobinized 
cells. Studies with HRI-deficient mice showed that HRI protects erythroid 
precursors from apoptosis induced by excessive production of globin chains and 
contributes to the microcytosis and hypochromia seen in iron deficiency, 
erythropoietic protoporphyria, and -thalassemia. 
 
1.3.7 Iron and Hypoxia Sensing 
 
The hypoxia-sensing pathway may also contribute to cellular iron homeostasis. 
Prolyl and asparaginyl hydroxylases, which inactivate the HIF transcription factors, 
are not only sensitive to oxygen tension but also to iron concentrations because 
they use iron as a catalytic cofactor. In support of the potential role of HIF in iron 
regulation, tissue-specific deletion of HIF2a in mouse enterocytes decreased 
intestinal iron absorption as well as the expression of DMT1 in enterocytes (46). 
HIF2a bound to the DMT1 promoter and transactivated it. The broader physiologic 
function of HIF in cellular iron homeostasis still remains to be established and may 
vary in different tissues depending on oxygen tension and other factors. 
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1.4 Systemic iron homeostasis  
 
1.4.1 The Central Role of Hepcidin  
 
Systemic iron homeostasis encompasses the regulatory circuitry that controls the 
absorption of dietary iron, the concentration of iron in extra-cellular fluid and blood 
plasma, and the release of iron from macrophages involved in iron recycling and 
from iron-storing hepatocytes. It now appears that there is a single systemic 
regulator of iron, the hepatic peptide hormone hepcidin.  
 
1.4.2 Hepcidin Synthesis and Structure 
 
Human hepcidin is predominantly produced by hepatocytes as a 25 amino acid 
peptide (2789.4 Da) (47,48), that is secreted into the circulation. Subsequent 
amino-terminal processing of the 25 amino acid form can result in the appearance 
of 2 smaller hepcidin forms of 22 and 20 amino acids. These hepcidin peptides 
form a hairpin structure, with 4 intramolecular disulfide bridges (Fig. 3) (49). On the 
basis of some studies, investigators have reported that hepcidin binds divalent 
metals (Cu2+, Fe2+, Zn2+, and Ni2+), but these findings are inconsistent, e.g., 
some studies have suggested the presence of iron in the core of the peptide in a 
tetrahedral sulfur coordination (50-52), whereas others provide evidence for an 
amino-terminal Cu(2+)– Ni(2+)-binding (ATCUN) motif (53,54). The ability of 
hepcidin to bind iron and other divalent metals suggests there may be a 
nonhormonal role for hepcidin in iron metabolism or a conformational mechanism 
for uptake of divalent metals as part of hepcidin’s hormonal role in regulating 
ferroportin degradation. 
Much is still unknown on the origin of the smaller isoforms of hepcidin, although 
data suggest that calcium-independent tissue activity in pancreas extracts might 
lead to the systemic N-terminal truncation of hepcidin-25 to hepcidin-22, and that 
dipeptidylpeptidase 4 is involved in the processing of hepcidin-22 into hepcidin-20 
(55,56). Under physiological conditions hepcidin-20 and hepcidin-22 are present in 
the urine, but not, or at very low concentrations, in the serum (57-59). Interestingly, 
these smaller hepcidin isoforms occur only in serum of patients with diseases that 
are associated with increased concentrations of hepcidin-25, such as acute 
myocardial infarction (AMI), sepsis, anemia of chronic disease (ACD), metabolic 
syndrome, and chronic kidney disease (CKD) (60-63). In vivo studies in mice have 
demonstrated that only full-length 25 amino acid hepcidin induces significant 
hypoferremia when injected intra-eritoneally (64). These findings are corroborated 
by in vitro studies that showed that the truncated 22 amino acid and 20 amino acid 
forms have greatly diminished and almost complete loss of ferroportin regulatory 
activity, respectively, compared with 25 amino acid hepcidin (65). 
Recent studies have demonstrated hepcidin expression by cells other than 
hepatocytes, although at much lower levels by comparison. These include kidney 
tubule, heart, retina, monocytes, neutrophils, fat cells, alveolar cells, pancreatic -
cells, and cardiomyocardal cells (66-72). The hepcidin produced by these cells, 
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however, is unlikely to make a significant contribution to systemic circulating 
concentrations, but may exert local effects in these tissues. 
 
 
 
 
Fig. 3. Molecular structure of hepcidin. A model of the structure of hepcidin-25 
according to Jordan et al. (3) is shown, with the -sheets (grey arrows), the peptide 
backbone (grey), the disulfide bonds (1–8, 2–4, 3–6, and 5–7) (yellow), positively 
charged arginine and lysine residues (blue), and the negatively charged aspartic 
acid residue (red). 
 
1.4.3 Hepcidin Kinetics 
 
Circulating hepcidin was recently found to be bound to 2-macroglobulin with 
relatively high affinity and to albumin with relatively low affinity. On the basis of 
theoretical calculations, 11% of hepcidin was estimated to be freely circulating (28). 
Whether binding to these carrier molecules influences the functional properties of 
hepcidin is uncertain. 
Hepcidin clearance is assumed to occur via cellular codegradation with ferroportin 
at its sites of action, and via excretion by the kidneys. Because of its low molecular 
weight and small radius, unbound hepcidin is likely to freely pass into the 
glomerular filtrate. In small studies in humans the fractional excretion of hepcidin 
has been calculated to be as low as 0%–5% (73,74), either because it is 
reabsorbed, similarly to other small peptides, or because it is not freely filtered. 
Evidence for the latter explanation comes from the finding of increases of only 1- to 
6-fold of serum hepcidin concentrations in patients with glomerular dysfunction (61, 
62, 24, 75) compared with the 20- to 30-fold increase of serum 2-microglobulin. 
The excretion of the latter low molecular weight protein is known to be almost 
completely governed by glomerular filtration. It is possible that binding to2-
macroglobulin or other carrier proteins prevents circulating hepcidin from being 
freely filtered. Alternatively, the otherwise expected increased circulating 
14 
 
concentrations in patients with decreased renal filtration may be offset by a 
compensatory feedback decrease in hepatic hepcidin production. 
It is speculative, but conceivable, that under certain conditions hepcidin escapes 
renal tubular reabsorption. This lack of reabsorption may play a role in several 
disorders of iron metabolism that are associated with tubular dysfunction and 
increased concentrations of urine hepcidin, such as inflammation, iron overload, 
and malaria (77,78). Possible local tubular production of hepcidin must also be 
taken into account in the interpretation of urine as a mirror of serum hepcidin 
concentrations in such studies (79) as well as possible defective tubular 
reabsorption of hepcidin. Additional studies to investigate the possibility that local 
urinary infections or tubular dysfunction can contribute to hepcidinuria are 
warranted. 
 
1.4.4 Hepcidin Function 
 
Hepcidin-25 is thought to be the major regulator of dietary iron absorption and 
cellular iron release. It exerts its regulatory function by counteracting the function of 
ferroportin, the major cellular iron exporter in the membrane of macrophages, 
hepatocytes, and the basolateral site of enterocytes. Hepcidin-25 induces the 
internalization and degradation of ferroportin (80-83), resulting in increased 
intracellular iron stores, decreased dietary iron absorption, and decreased 
circulating iron concentrations (Fig. 4). 
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Fig. 4. Iron uptake and recycling. Most of the used body iron is recycled from 
senescent erythrocytes by macrophages, and returned to the bone marrow for 
incorporation in erythroid precursors. The liver and RE macrophages function as 
major iron stores. Importantly, the total amount of iron in the body can be regulated 
only by absorption, whereas iron loss occurs only passively from sloughing of skin 
and mucosal cells as well as from blood loss. This results in the absorption and 
loss of 1–2 mg iron every day. Hepcidin, a peptide produced in the liver, controls 
the plasma iron concentration by inhibiting iron export by ferroportin from 
enterocytes and macrophages. As a consequence, an increase in hepcidin 
production leads to a decrease in plasma iron concentrations. Hepcidin expression 
is regulated by body iron status, inflammation, erythroid iron demand, and hypoxia 
via regulation pathways involving the expression of the genes HFE, transferrin 
receptor 2 (TFR2), and hemochromatosis type 2 (juvenile) (HFE2) (also known as 
HJV). Adapted from (142, 223 ). 
 
In addition to its role in regulating systemic iron metabolism, hepcidin may also 
contribute to host defense. Hepcidin was originally identified as an antimicrobial 
peptide (58). Although in vitro studies suggest bacteriocidal effects of hepcidin, 
these effects would require concentrations higher than those observed in the 
circulation. Such concentrations may be achieved locally, for instance in 
phagosomes of infected macrophages (84). Hepcidin might also contribute 
indirectly to host defense by reducing plasma iron concentrations. Iron is necessary 
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for microbial growth, and reductions in plasma iron are bacteriostatic. Moreover, 
hepcidin was found to modulate lipopolysaccharide-induced transcription in both 
cultured macrophages and in vivo mouse models (85). This latter observation 
suggests a role for hepcidin in modulating acute inflammatory responses to 
bacterial infection. 
Hepcidin produced by various cell types other than hepatocytes may have local 
effects in these tissues. Through an autocrine interaction with ferroportin, local 
hepcidin may protect the nearby cells from iron deficiency, prevent extracellular 
oxidative stress, affect inflammatory reponses, and/or deplete extracellular iron 
pools that are available for extracellular pathogens (86,87). Although the smaller 
forms of hepcidin do not elicit a hypoferremic response, it is currently unknown 
whether they retain other identified biological functions of hepcidin-25 (e.g., in host 
defense or in metal binding) (88). 
 
1.4.5 Hepcidin Regulation 
 
Several physiologic and pathologic processes regulate the synthesis of hepcidin 
(Figure 5) [reviewed in (89)]. Situations in which demand for circulating iron is 
increased (particularly erythropoietic activity) elicit a decrease in hepatocellular 
hepcidin synthesis. These conditions include iron deficiency, hypoxia, anemia, and 
conditions characterized by increased erythropoietic activity. A decrease in 
hepcidin results in the release of stored iron and an increase in dietary iron 
absorption. On the other hand, infection and inflammation cause an increase in 
hepcidin synthesis. This increased synthesis leads to a deficiency of iron available 
for erythropoiesis, and is considered to be the mechanism underlying 
reticuloendothelial (RE) iron sequestration, intestinal iron absorption impairment, 
and low serum iron concentrations characteristic of anemia of chronic disease. 
The functional signaling routes by which (a) iron status, (b) erythropoietic activity, 
(c) hypoxia, and (d) inflammation affect hepcidin expression are increasingly being 
investigated. These routes comprise 4 highly interconnected regulatory pathways 
(Figure 5). 
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Fig. 5. Molecular and functional pathways of hepatocyte hepcidin synthesis. Three 
molecular pathways can be distinguished: the HFE/TfR2, BMP/SMAD, and 
JAK/STAT. This proposed model depicts 2 iron signals to hepcidin, 1 mediated by 
intracellular iron stores (Fe) and the other by circulating iron (Tf-Fe2). 
Hepatocellular iron stores increase the expression of BMP-6, which serves as an 
autocrine factor by interacting with surface BMP receptors. HJV is a BMP 
coreceptor that augments BMP binding. The consequent activation of intracellular 
SMAD proteins transduces a signal to increase hepcidin transcription. HJV is 
subject to cleavage by furin, which is regulated by iron and hypoxia, to form a 
soluble component (sHJV) (61 ). sHJV can subsequently act as a decoy coreceptor 
and antagonist of BMP-6 induced hepcidin synthesis. Under low iron conditions 
membrane bound HJV is also cleaved by matriptase-2 (scissors) again weakening 
the BMP-6 signal. Extracellular Tf-Fe2 mediates a second iron signal. In this 
scheme, Tf-Fe2 displaces HFE from TfR1. HFE is then liberated to interact with 
TfR2. The HFE–TfR2 complex activates hepcidin transcription via BMP/SMAD 
signaling. Several studies have provided indirect evidence for the involvement of 
the hepatic ERK/MAPK signaling pathway in hepcidin regulation by iron through 
TfR2 and/or HFE [reviewed in (44 )]. Recent studies in mice, however, demonstrate 
that acute and chronic enteral iron administration did not activate the ERK/MAPK 
pathway, which suggests that this route may not be of physiological relevance for 
iron homeostasis in vivo (46). Hypoxia influences liver-specific stabilization of HIF-
1, which induces matriptase-2 and the subsequent cleavage of HJV (62 ). The 
latter pathway may be synergistic to the increased release of sHJV upon its 
cleavage by furin under hypoxic conditions. Erythropoiesis is controlled in part by 
EPO production in the kidney and communicates with the hepatocyte by the 
proteins GDF15 and TWSG1, which inhibit the BMP/SMAD signaling to hepcidin. 
Inflammatory stimuli, such as IL-6, induce hepcidin synthesis through the janus 
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kinase/signal transducer and activator of transcription-3 (JAK/STAT) pathway. 
These pathways have recently been reviewed (44). Adapted from (133, 224). pO2, 
partial oxygen pressure; sTfR: soluble TfR; BMPR, BMP receptor; IL-6R: IL-6 
receptor. 
 
1.4.5.1 Regulation by Systemic Iron Availability  
 
HFE has been suggested to act as a bimodal switch between two sensors of the 
concentration of Tf-Fe2, TfR1, and TfR2, on the plasma membrane of hepatocytes 
(90). This model is supported by the following findings: HFE binds the ubiquitously 
expressed TfR1 at a site that overlaps the transferrin binding domain, and Tf-Fe2 
thus competes with HFE binding to TfR1. By contrast, TfR2 can bind both HFE and 
Tf-Fe2 simultaneously (91). Mice bearing an engineered TfR1 mutation with 
increased HFE binding show low hepcidin expression and systemic iron overload 
similar to HFE-deficient mice, suggesting that the TfR1 sequesters HFE to prevent 
its participation in hepcidin activation. Conversely, mutations that abolish the HFE-
TfR1 interaction or mice with increased HFE levels display elevated hepcidin 
expression and succumb to iron deficiency (92). Hepcidin activation by 
holotransferrin requires both HFE and TfR2 (93). These observations support a 
model in which high concentrations of Tf-Fe2 displace HFE from TfR1 to promote 
its interaction with TfR2, which is further stabilized by increased Tf-Fe2 binding to 
the lower-affinity TfR2. The HFE- TfR2 complex then activates hepcidin 
transcription. Future research is needed to establish the stoichiometry of the 
proteins involved in this “Tf-Fe2-sensing complex” and to clarify whether HJV is 
part of it. 
Although HFE and TfR2 clearly contribute to hepcidin activation, the BMP signaling 
pathway is quantitatively the most critical. By as yet only partially understood 
mechanisms, it integrates signals from the “Tf-Fe2-sensing complex” and the 
hepatocytic iron stores. Central to the latter is BMP6, which is positively regulated 
by iron.  
BMP are a subfamily of cytokines that belong to the transforming growth factor- 
superfamily (94). 
Bmp6 knockout mice show hepcidin deficiency and tissue iron overload (95,96), 
although BMP2 and BMP4 can also bind to HJV. BMP6 is thought to act in an 
autocrine manner analogous to its role in chondrocyte differentiation (97) to induce 
signaling via Hemojuvelin (HJV), a glycophosphatidylinositol (GPI)-linked 
membrane protein (98), the BMP coreceptor that adapts BMP receptors for iron 
regulation (99). The BMP/HJV complex joins the type I (Alk2 and Alk3) and the 
type II (ACTRIIA) BMP receptors to induce phosphorylation of receptor activated 
SMAD (R-SMAD) proteins, Smad1, Smad5, and Smad8 in the cytoplasm, and 
subsequent formation of active transcriptional complexes involving the co-SMAD 
factor, SMAD4 (100). 
Two sequence motifs (the proximal BMP-RE1 and the distal BMP-RE2) of the 
hepcidin promoter are critical for transcription via HJV, BMP6, and SMAD4 (101), 
and the promoter region that contains BMP-RE2 confers iron responsiveness to the 
hepcidin promoter (102). Multiple lines of evidence highlight the importance of HJV/ 
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BMP/SMAD signaling for hepcidin activation: (1) mice lacking HJV show attenuated 
R-SMAD phosphorylation in the liver (99), (2) administration of BMP2 and BMP6 to 
mice induces hepcidin mRNA and decreases serum iron levels, (3) BMP 
antagonists (such as dorsomorphin) inhibit hepcidin mRNA expression and 
increase serum iron levels (103), (4) liver-specific disruption of the co-SMAD4 
causes severe iron overload with diminished hepcidin transcription (100), and (5) 
the inhibitory iSMAD7 potently suppresses hepcidin transcription in cellular models 
(104). Interestingly, R-SMAD phosphorylation is also attenuated in mice lacking 
HFE, suggesting that HJV and HFE act together to activate hepcidin transcription 
(105,106). Crosstalk between the BMP/SMAD and p38-MAPK signaling pathways 
activates hepcidin mRNA expression in response to Tf-Fe2 in primary hepatocytes. 
Activation of p38-MAPK and Erk1/2 depends on both HFE and TfR2, as this 
pathway is attenuated in mice lacking HFE or TFR2 and in double-knockout mice 
(107). 
Apart from mutations of the hepcidin gene itself, only HJV mutations lead to a near 
absence of hepcidin expression and the most severe form of hereditary 
hemochromatosis. Thus, HJV is central for hepcidin expression, and the point of 
convergence of multiple regulatory inputs.  
The membrane-associated protease TMPRSS6 that is mutated in IRIDA physically 
interacts with HJV and cleaves HJV when both proteins are expressed on the cell 
surface, suggesting that HJV is the major TMPRSS6 target for iron regulation 
(108). Genetically, the combined deficiency of HJV and TMPRSS6 causes iron 
overload, suggesting that TMPRSS6 acts upstream of HJV (109,110). Increased 
HJV surface expression has however yet to be confirmed in Tmprss6-deficient 
mice or IRIDA patients. 
Furin-mediated cleavage releases HJV from cells to generate soluble HJV (sHJV), 
which antagonizes BMP-dependent hepcidin activation. Furin mRNA expression is 
regulated by iron and hypoxia, conferring another level of control (108). Because of 
the high HJV expression in skeletal muscle, it is tempting to speculate that sHJV is 
released as a muscle signal in iron deficiency. Importantly, cleavage of HJV by 
other proteases does not seem to be redundant with that by TMPRSS6, as lack of 
TMPRSS6 activity causes iron deficiency in humans and mice. Future work needs 
to address how TMPRSS6 expression and activity are regulated, and the relative 
contributions of TMPRSS6 and furin to the regulation of HJV and systemic iron 
homeostasis need to be further defined. 
Neogenin, a DCC (deleted in colorectal cancer) family member, appears to 
stabilize HJV to enhance BMP signaling and hepcidin expression. Consistently, 
mice lacking neogenin exhibit hepatic iron overload, low hepcidin levels, and 
reduced BMP signaling (111). 
Another molecule that may negatively regulate hepatic BMP signaling for hepcidin 
production is SMAD7, an inhibitory SMAD protein that is induced by TGF- 
signaling. SMAD7 appears to antagonize TGF- signaling by acting in a negative-
feedback loop. Similar to the expression of hepcidin and Bmp6, hepatic mRNA 
levels of Smad7 increase with chronic dietary iron loading (112). In primary murine 
hepatocytes, SMAD7 expression is induced by BMP6, whereas SMAD7 
overexpression greatly reduces hepcidin mRNA levels and abolishes the hepcidin 
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response to BMP6 (104). These findings suggest that SMAD7 may function to 
provide negative feedback to dampen BMP signaling for hepcidin production. The 
relative contribution of SMAD7 activity to hepcidin regulation in vivo has yet to be 
established. 
 
1.4.5.2 Regulation by Hypoxia 
 
Liver-specific stabilization of the hypoxia-inducible factor 1 (HIF1) and HIF2 
decreases hepcidin expression, and chemical HIF stabilizers can suppress 
hepcidin mRNA expression in hepatoma cells (113). These findings have raised 
the possibility that iron-dependent prolyl hydroxylases involved in HIF degradation 
may act as hepatic iron sensors. Whether or not HIFs directly bind to the hepcidin 
promoter is currently controversial. 
In vivo, hypoxia induces erythropoietin (EPO) synthesis, which in turn stimulates 
erythropoiesis. EPO injection into mice reduces hepcidin levels in a dose-
dependent manner and can override signals that activate hepcidin expression. 
Even low dose EPO injections in human volunteers promptly decrease urinary 
excretion of hepcidin (114). Because experimental blockade of erythropoietic 
activity prevents its effect, EPO likely suppresses hepcidin by stimulation of 
erythropoiesis rather than more directly (115).  
 
1.4.5.3 Regulation by Inflammatory and Stress Signals 
 
The inflammatory cytokines IL1 and IL6 are both potent inducers of hepcidin 
expression, a response whose clinical importance for ACD has been discussed 
above. IL6 activates the Janus kinase (JAK)/signal transducer and activator of 
transcription (STAT) signaling pathway, which activates the hepcidin promoter via a 
STAT-binding motif close to the transcription start site (116). The BMP signaling 
pathway also contributes to the inflammatory response via SMAD4 (100,101). Mice 
injected with lipopolysaccharide (LPS) augment hepcidin transcription even in the 
context of iron overload; likewise, LPS counteracts the diminished hepcidin 
expression in response to iron deficiency, suggesting that the two signals are 
integrated at the hepcidin promoter and that inflammatory and iron stores 
regulators operate independently rather than following a strict hierarchy (117). 
Hepcidin expression is also increased by endoplasmic reticulum (ER) stress. This 
stress response can be controlled by the transcription factor cyclic AMP response 
element-binding protein H (CREBH) (118) or by the stress-inducible transcription 
factors CHOP and C/EBPalpha (119). It has also been suggested that increased 
hepcidin transcription and iron deprivation may represent defense mechanisms 
against excessive cell proliferation and cancer, possibly by binding of the p53 
tumor suppressor protein to a response element in the hepcidin promoter (120). 
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1.4.5.4 Hepcidin Regulation by Anemia 
 
Anemia and ESA administration are potent inhibitors of hepcidin expression, 
allowing greater iron availability for erythropoiesis (121,122). The dominance of the 
inhibitory effect of anemia and erythropoietic drive over the stimulatory effects of 
iron on hepcidin regulation is evidenced in -thalassemias. In this disease, hepcidin 
levels remain low because of very high erythropoietic activity, even in the face of 
increasing serum iron and tissue iron deposition that ultimately lead to fatal iron 
overload (123,124). Although ESAs have been shown to inhibit hepcidin 
transcription in isolated liver cells in vitro through erythropoietin receptor signaling 
and inhibition of C/EBP binding to the hepcidin promoter (125), 2 studies 
suggested that in vivo, the inhibitory effects of anemia or ESAs on hepcidin 
expression require erythropoietic activity. These studies showed that inhibition of 
erythropoiesis by chemotherapy, an ESA-blocking antibody, or irradiation 
prevented hepcidin suppression by either ESAs or anemia (115,126). It has been 
suggested that proliferating erythrocyte precursors may secrete a substance that 
circulates to the liver to inhibit hepcidin expression. Recently, 2 modulators of the 
TGF- β/BMP superfamily signaling pathway, growth and differentiation factor 15 
(GDF15) and twisted gastrulation (TWSG1), were reported to be secreted by 
erythroblast precursors and have a role in hepcidin suppression in thalassemia 
(127,128). GDF15 is a TGF-β superfamily ligand that activates SMAD2 and 
SMAD3, and TWSG1 can function as a BMP agonist or antagonist (129-132). 
Hepcidin suppression in response to phlebotomy or hemolysis depends on intact 
erythropoietic activity in mouse models: irradiation and cytotoxic inhibition of 
erythropoiesis prevent hepcidin suppression (115). GDF15 and TWSG1 are both 
released by erythroid precursors. High doses of GDF15 are detectable in the 
serum of patients with ineffective erythropoiesis such as β-thalassemia (127). Such 
pathological concentrations of GDF15 can suppress hepcidin transcription in cell 
models, but the underlying molecular mechanism has not yet been characterized. 
By contrast, lower GDF15 concentrations fail to suppress hepcidin in cellular 
models and are apparently ineffective in patients with sickle cell anemia, 
myelodysplastic syndrome, and ACD. TWSG1 expression is increased in 
thalassemic mice, where it is produced during early erythroblast maturation. In 
cellular models, the BMP-binding protein TWSG1 inhibits BMP-dependent 
activation of Smad-mediated signal transduction that leads to hepcidin activation 
(128). Correlations between TWSG1 expression, serum iron parameters, and 
hepcidin levels have not yet been studied in human anemias. 
Notably, an iron phenotype was not described in mice with GDF15 dysregulation, 
and sera from patients with sickle cell anemia or myelodysplastic syndrome did not 
have increased GDF15 levels (133,134), suggesting that the role of these proteins 
in hepcidin suppression may be limited to anemias such as -thalassemia with 
ineffective erythropoiesis. 
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1.4.6 Hepcidin Assays 
 
Hepcidin excess has been postulated to have a role in the anemia of patients with 
CKD/ESRD because of decreased renal clearance and induction by inflammatory 
stimuli, particularly in patients who are ESA resistant. However, it is only recently 
that hepcidin assays have been developed to start to investigate these hypotheses. 
The development of immunochemical methods to detect mature hepcidin has been 
complicated by hepcidin’s small size and its conservation in animal species. The 
first described hepcidin assay was an immunodot assay to measure urinary 
hepcidin. However, this assay is semiquantitative, laborious, and not suitable for 
serum hepcidin measurements (75). A commercially available immunoassay was 
developed to detect serum prohepcidin, but prohepcidin levels do not correlate with 
biological activity, iron status, or inflammation (135,136). Others have developed 
mass spectroscopic techniques to measure mature hepcidin in serum and urine. 
Although this technique has the potential advantage of being able to distinguish 
among hepcidin-25, hepcidin-22, and hepcidin-20, these assays depend on 
expensive equipment that is not widely available, and most are semiquantitative, 
although more recent refinements are improving the quantitative ability (59,62,137-
139). In the last year, immunoassays to quantitate mature serum hepcidin have 
been developed, as well as an assay based on competition against hepcidin-25 
labeled with iodine 125 binding to a peptide identical to the ferroportin hepcidin-
binding site (88,140,141). A recently published round robin study comparing these 
various mass spectrometry and immunochemical-based methods to quantify 
urinary and plasma mature hepcidin has shown that absolute hepcidin 
concentrations differ widely between methods, but Spearman correlations between 
individual sample mean hepcidin values obtained using most methods generally 
were high for 7 of 8 methods tested. Analytical variance generally is low and similar 
for all methods, indicating the potential suitability of all methods to distinguish 
hepcidin levels of different samples. It was hypothesized that differences in 
absolute hepcidin levels between methods may be caused by the use of different 
calibrators, hepcidin aggregation, hepcidin protein binding, and/or the existence of 
hepcidin-25, hepcidin-22, and hepcidin-20 isoforms that may be detected to some 
extent by immunochemical methods, depending on the antibody used. This report 
called for efforts to further harmonize the various hepcidin assays (142). 
 
1.4.7 Hepcidin Excess and the Anemia of CKD 
 
Using the mentioned immunoassays to measure mature hepcidin, several groups 
now have confirmed that hepcidin levels are increased in patients with CKD and 
ESRD and inversely correlate with GFR (23-25) suggesting that decreased renal 
clearance contributes to the hepcidin increase in this patient population. Hepcidin 
levels are decreased by dialysis, but return to predialysis levels before the next 
dialysis session (143). Interestingly, 1 study using a mass spectrometry–based 
technique to distinguish among hepcidin-25, hepcidin-20, and hepcidin-22 
suggested that although hepcidin-25 was increased in patients with ESRD and 
total hepcidin (encompassing hepcidin-25, hepcidin-20, and hepcidin-22) 
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correlated inversely with estimated GFR in patients with CKD not requiring dialysis, 
no significant correlation was found between hepcidin-25 and estimated GFR in 
patients with CKD not requiring dialysis (63). These results need to be confirmed in 
larger studies. 
Hepcidin levels correlate with markers of iron burden in the CKD population, as in 
other patient populations, particularly serum ferritin (144). In multivariate analyses, 
ferritin level is the strongest predictor of serum hepcidin level. Hepcidin levels also 
are increased by iron administration in the CKD population, as in healthy controls. 
Interestingly, although hepcidin is stimulated by inflammation and has been 
increased in patients with inflammation, defined as high C-reactive protein (CRP) 
levels, initial studies of patients with CKD have not shown a consistent or robust 
correlation between levels of hepcidin inflammatory markers, such as CRP, 
erythrocyte sedimentation rate (ESR), or IL-6. One explanation for these findings 
may be related to the patient populations selected for these studies, some of which 
excluded patients with active illness or infection. 
Hepcidin levels are associated with anemia in dialysis patients, consistent with a 
role for hepcidin excess in the anemia of CKD; however, there is an inverse 
correlation between ESA dose and hepcidin level, arguing against a diagnostic role 
for hepcidin as a predictor of ESA resistance. The likely explanation for this finding 
is that ESA administration is an inhibitor of hepcidin expression in the CKD 
population, as in the general population. It has been proposed that the initial 
decrease in hepcidin levels after starting ESA therapy might be a better indicator of 
long-term responsiveness to ESAs (145). 
Given the limited number and size of studies to date, the unresolved issues 
surrounding hepcidin assays themselves, and the numerous factors that can 
modulate hepcidin levels in the CKD/ ESRD population, including iron 
administration, ESA administration, body iron burden, inflammation, renal 
clearance, and dialysis (Fig. 6), more studies are needed to determine whether 
hepcidin will have diagnostic utility as a measure of iron status, inflammatory 
status, and/or ESA responsiveness or resistance. 
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Figure 6. Hepcidin levels in patients with chronic kidney disease and end-stage 
renal disease. Hepcidin levels are increased in patients with chronic kidney disease 
and end- stage renal disease and reflect the balance of stimulatory factors: 
decreased renal clearance (GFR, glomerular filtra- tion rate), inflammation, and 
iron administration; and inhibitory factors: anemia, erythropoiesis-stimulating agent 
(ESA) administration, clearance by dialysis, and hypoxia. 
 
1.4.8 Current Management of ACD 
 
Anemia often complicates the underlying chronic diseases and is consistently a 
predictor of poor prognosis of the disease, longer hospitalization, cognitive 
impairment, heart failure and increased morbidity. 
Although survival benefits have not yet been tested in prospective randomized 
controlled trials, treatment of anemia has been demonstrated to improve the quality 
of life and energy levels for hemodialysis, cancer and rheumatoid arthritis patients 
with concurrent ACD (146-148).  
The treatment of choice in ACD is the cure of the underlying chronic disease. 
However, this is not possible for patients with incurable chronic diseases like 
cancers and chronic kidney disease. Current therapeutic management of ACD in 
the clinic involves increasing red blood cells by blood transfusions, erythropoiesis 
stimulating agents (ESAs) and/or iron administration.   
Anemia of chronic kidney disease (CKD) occurs primarily due to a complex 
interplay of erythropoietin deficiency, shortened red blood cell survival and iron 
deficiency. Early clinical trials involving recombinant human erythropoietin (rHU 
EPO) demonstrated increased hematocrit and reticulocytosis in anemia of patients 
(149). In 1989, the US FDA approved the use of the rHU EPO epoietin alpha for 
treatment of anemia of CKD. Subsequently, epoietin alpha and other similar ESAs 
have been used to treat anemia of rheumatoid arthritis, anemia of cancers and 
other chronic diseases (150-153). Not only did the ESAs improve hemoglobin 
levels, quality of life scores, energy levels and work capacity were also increased in 
patients with ACD (154,155).  
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However, some patients with ACD are poorly responsive to ESAs, leading to a 
requirement of higher dosing to achieve target hemoglobin levels. Clinical trial 
results from the Correction of Hemoglobin in Outcomes and Renal Insufficiency 
(CHOIR) and Trial to Reduce cardiovascular Events with Aranesp Therapy 
(TREAT) revealed that patients receiving ESA doses to achieve target hemoglobin 
levels of >13g/dL have a higher incidence of adverse outcomes such as 
cardiovascular events, strokes, progression of cancers and even death. These 
findings in CHOIR and TREAT prompted a US Food and Drug Administration black 
box warning on the labels of ESAs and a cap in criteria of hemoglobin target levels 
at 11-12g/dL (156-159).  
Due to the functional iron deficiency in ACD, iron supplementation is frequently 
administered either alone or in combination with ESAs. Although oral iron 
supplement is widely available, cheap, and easy to administer, it is ineffective 
compared to intravenous (IV) iron therapy in ACD patients owing to hepcidin 
mediated block in intestinal iron absorption. IV iron administration alone has been 
used successfully to raise hemoglobin levels in patients with inflammatory bowel 
disease associated anemia (160). The DRIVE (Dialysis Patient’s Response to IV 
iron and with Elevated Ferritin) trial revealed that anemic hemodialysis patients 
receiving intravenous ferric glucconate and erythropoietin had a faster and better 
response in hemoglobin levels compared to those receiving only erythropoietin 
alone. This suggests that IV iron can relieve the functional iron deficiency in ACD, 
at least in patients with elevated ferritin and reduced transferrin saturation (161). 
Subsequent studies confirm the observation that correction of the functional iron 
deficiency with IV iron supplementation can significantly improve the effects of 
ESAs (162) and even reducing the required ESA dosage (163).   
A recent double-blinded trial, however, finds no additional benefit of providing iron 
therapy and the ESA darbopoietin alfa in patients with chemotherapy-associated 
anemia (164). The negative result could be due to higher total body iron load 
(ferritin levels) or different iron dosing amounts, in this patient population compared 
to other studies. However, a closer analysis of the data suggests that patients with 
lower hepcidin levels responded better to parenteral iron with ESAs compared to 
patients with high hepcidin levels (165).  
While IV iron can overcome some degree of iron blockade in ACD, there is also a 
safety concern for iron therapy in ACD associated with infection or ACDs with 
coexisting infection. Based on the idea that pathogens need iron for growth, 
providing iron therapy may be detrimental as it fuels the pathogen’s iron needs for 
survival and propagation. Recommendations for management of these patients 
tend to err on the safe side while not inhibiting the usage of iron (166).  The cause 
for concern arose from the Pemba trial where universal supplementation of iron 
and folic acid to children with iron deficiency anemia in malaria endemic regions 
resulted in a higher incidence of sudden illness and death (167).  
Additionally, administering IV iron has been shown to increase hepcidin levels in 
CKD patients on hemodialysis (24). The rise in hepcidin would later cause iron 
blockade in the macrophages, rendering the administered iron unavailable for 
erythropoiesis, thereby potentially worsening the underlying pathophysiology of 
ACD. Consistent with this, ferritin levels were also increased in these patients (24). 
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The long term effects of IV iron therapy and concurrent increased iron stores in 
ACD patients have not been investigated.   
Thus, conventional methods using ESAs and iron therapy do not fully address the 
root cause of the pathophysiology of ACD, that is, excess hepcidin. The use of 
ESAs is not without risk and may even be fatal. Iron therapy also carries risks of 
worsening underlying infection and exacerbating anemia by increasing hepcidin. 
Alternative therapies, which target hepcidin synthesis and its action, are discussed 
below. 
 
1.4.9 New Therapeutic Strategies for ACD That Target the Hepcidin–
Ferroportin Axis 
 
Alternative therapies for ACD that target the hepcidin–ferroportin axis are attractive 
treatment options. Therapeutics that decrease hepcidin production and increase 
ferroportin activity would improve iron bioavailability from the diet and would 
mobilize existing body iron stores for erythropoiesis, without the adverse risks from 
supraphysiologic iron or ESA therapies. A number of strategies that inhibit hepcidin 
function (direct hepcidin antagonists), prevent the transcription of hepcidin 
(hepcidin production inhibitors), or promote resistance of ferroportin to hepcidin 
action (Ferroportin agonists/stabilizers) are currently under investigation (Fig. 7, red 
lines. 
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Fig. 7. Inhibitors that target the hepcidin–ferroportin axis are potential therapeutic 
avenues for treating ACD. As excess hepcidin leads to ACD, blocking the signaling 
pathways responsible for hepcidin synthesis, neutralizing hepcidin's effect on 
ferroportin or promoting ferroportin function may ameliorate ACD (red lines). 
Hepcidin production can be effectively inhibited by the following BMP6–HJV–
SMAD inhibitors: soluble HJV.Fc protein (Ferrumax Pharmaceuticals), monoclonal 
anti-BMP6 antibodies, or the glycosaminoglycan heparin sequester BMP6, 
preventing its interaction with BMPR and membrane anchored HJV; the 
dorsomorphin derivative LDN-193189 inhibits BMP Type I receptor activity. Alcohol 
may also inhibit hepcidin synthesis by dampening the BMP-SMAD pathway. Anti-
inflammatory therapeutics suppress IL-6-mediated hepcidin gene expression by: 
blocking antibody to IL-6 Siltuximab (Janssen Biotech); neutralizing antibody to IL-6 
receptor Tocilizumab (Genentech); or using STAT3 pathway inhibitors, which block 
the phosphorylation of STAT3 (AG490) or its transcription factor binding activity 
(PpYLKTK). Vitamin D can also downregulate hepcidin transcription, but the 
mechanism is unknown. Hepcidin protein expression or activity may be inhibited 
directly by: hepcidin siRNA (Alnylam Pharmaceuticals); hepcidin antisense 
oligonucleotides (Xenon Pharmaceuticals and ISIS Pharmaceuticals); or direct 
hepcidin antagonists, including anti-hepcidin antibodies (Amgen, Eli Lilly), hepcidin 
sequestering anticalins (Pieris AG), or hepcidin binding spiegelmers (NOXXON 
Pharma). Ferroportin agonists/stabilizers, which modify the ferroportin–hepcidin 
interaction or increase ferroportin's resistance to hepcidin (Eli-Lilly), may 
theoretically ameliorate anemia by maintaining ferroportin activity and allowing iron 
influx. 
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1.4.9.1 Direct Hepcidin Antagonists 
 
1.4.9.1.1 Antihepcidin antibodies 
 
Therapeutic monoclonal antibodies have revolutionized the management of 
cancers and autoimmune diseases (168). One strategy under investigation for 
neutralizing hepcidin activity is with antihepcidin antibodies. Studies performed by 
Amgen demonstrated that a humanized antihepcidin monoclonal antibody 
(mAb2.7) can reverse iron restriction and prevent anemia progression in a mouse 
model of anemia of inflammation when used in combination therapy with ESA 
(169). However, neither antihepcidin antibodies nor ESA alone could prevent the 
anemia progression in their model. Recently, the authors performed a 
pharmacokinetics study on normal cynomolgus monkeys and determined that a 
dose of 300 mg/kg per week of another monoclonal antihepcidin antibody 
(Ab12B9m) was required to effectively decrease free hepcidin levels below 
baseline. Although Ab12B9m has a high affinity (Kd = 1 pM) for hepcidin and a 
long half life estimated at 16.5 days, the high rate of hepcidin production (7.6 
nmol/kg/h) would require large quantities of the antibody to achieve significant 
blocking effect (170). A US patent (#7820163) was recently assigned to Eli Lilly 
and Company for the use of antihepcidin monoclonal antibodies as treatment for 
anemia. These antibodies bind with high affinity (Kd = 80 pM) to human and 
monkey hepcidin and can block its action on ferroportin. In a cynomolgus monkey 
IL-6-induced hypoferremia model, antihepcidin monoclonal antibody therapy 
prevented the hypoferremia for up to 12 hr (171). The antibodies are currently in 
Phase 1 clinical trials for the treatment of anemia according to the Lilly company 
website (172). 
 
1.4.9.1.2 Short interference RNA and antisense oligonucleotides against hepcidin 
 
RNA interference (RNAi) and gene silencing antisense oligonucleotides that target 
transcription or translation of hepcidin represent another approach to developing 
therapeutics for ACD. Amgen recently described a short hairpin RNA (shRNA) 
strategy against hepcidin that successfully reduced its expression and corrected 
anemia in a mouse model of anemia of inflammation . Profound suppression of 
hepcidin alone was sufficient to redistribute stored body iron into the circulation and 
to correct the anemia in these mice. Moderate hepcidin suppression alone was 
unable to correct the anemia and required ESA coadministration to be effective 
[169]. Alnylam Pharmaceuticals is currently developing hepcidin RNAi (ALN-HPN) 
to silence hepcidin gene expression and increase serum iron levels. They expect to 
file an Investigational New Drug application in 2012 for ALN-HPN for the treatment 
of erythropoietin resistant ACD and iron refractory anemias (173). 
Significant technical challenges will need to be overcome to apply RNAi 
therapeutics for treatment in humans. The challenges include effective design of 
the RNAi without off-target effects, instability of RNAi in vivo, lack of 
biocompatibility of the delivery system, and nonspecific targeted delivery to 
organs/cells (174). Viral delivery systems, while highly efficient in delivering shRNA 
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or RNAi, can carry risks of random genome integration and induction of 
unfavorable immunological responses (175). Notably, shRNA against hepcidin 
delivered in an AAV8 capsid serotype virus system caused some deaths in mice. 
Antisense oligonucleotides that inhibit translation of hepcidin or its regulators such 
as HJV are currently in discovery stages of development. Xenon Pharmaceuticals 
and ISIS Pharmaceuticals have been collaborating since 2010 to develop this 
technology to treat anemia of infection (176). Systemic delivery of antisense 
molecules results in preferential delivery to the liver, making them appealing agents 
to target hepcidin (177). While the approach is theoretically feasible to dampen 
hepcidin production, it has not been demonstrated that antisense hepcidin 
oligonucleotides are effective in increasing serum iron concentration and 
ameliorating inflammatory anemia in vivo. In addition, antisense oligonucleotides 
share similar technical challenges with RNAi therapies as described before. 
 
1.4.9.1.3 Hepcidin binding proteins 
 
Lipocalins are secreted proteins whose four-peptide loop cavity forms a binding site 
with high structural plasticity (178). Their simple structure and natural ability to 
recognize and bind various small hydrophobic ligands and specific cell-surface 
receptors make them suitable for engineering a new class of therapeutic proteins 
for specific blocking purposes (179). These engineered lipocalins are known as 
anticalins. Scientists at the Technical University Munich and Pieris AG have 
developed an anticalin PRS-080, which exhibits high affinity binding (Kd = 0.1 nM) 
to human hepcidin based on enzyme-linked immunosorbent assay (ELISA) studies 
and surface plasmon resonance. They also demonstrated that pretreatment with 95 
mg/kg of PRS-080 can completely neutralize the short-term hypoferremia induced 
by injection of synthetic human hepcidin in mice (180). According to their company 
website, Pieris AG recently received support of six million Euro from a EU FP7 
Grant to progress PRS-080 from preclinical development through Phase 1b clinical 
trials (181). Further characterization of this hepcidin blocking anticalin will be 
needed to determine its safety, tolerability, and efficacy for relieving hepcidin-
mediated iron blockade in ACD. 
 
1.4.9.1.4 Hepcidin binding spiegelmers 
 
Aptamers are synthetic single-stranded oligonucleotides that bind ligands with high 
affinity, representing a novel class of oligonucleotide structures suitable for 
blocking purposes. Spiegelmers (Spiegel, which means “mirror” in German) are 
mirror image aptamers trademarked by NOXXON Pharma. Spiegelmers are 
attractive therapeutic agents because of their high resistance to nuclease activity, 
good stability in vivo, and low immunogenicity (182,183). NOX-H94 is a 
polyethylene glycol conjugated (PEGylated) spiegelmer developed by NOXXON 
Pharma AG that specifically targets and binds to human hepcidin (184). It was 
demonstrated to be effective in vitro by blocking hepcidin-induced ferroportin 
degradation in cells. Additionally, it was able to increase serum iron concentration 
in a IL-6 induced high hepcidin model in cynomolgus monkeys (185). Preclinical 
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studies suggest spiegelmers are safe, well tolerated, and effective in animals (186-
190). The company has initiated a first-in-human clinical trial to evaluate safety, 
tolerability, and efficacy of NOX-H94. Administration of PEGlyated aptamers was 
recently shown to lead to an accumulation of the oligonucleotides in macrophages 
throughout the body, it is currently unknown whether chronic systemic 
administration of PEGylated aptamers will lead to adverse effects (191). 
 
1.4.9.2 Hepcidin Production Inhibitors 
 
Given the rapid rate of hepcidin production, targeting the positive regulators of 
hepcidin to reduce its expression may be more effective than direct blockade of 
hepcidin action. Two signaling pathways have been targeted thus far to inhibit 
hepcidin synthesis: BMP6–HJV–SMAD pathway inhibitors and IL-6–STAT3 
pathway inhibitors. 
 
1.4.9.2.1 BMP6–HJV–SMAD pathway inhibitors 
 
The BMP family of ligands represents the largest subgroup of the TGFβ 
superfamily. Twenty BMP family members have been identified with diverse 
functions including embryogenesis, osteogenesis, neurogenesis, and iron 
metabolism (192,193). Like other members of the family, BMP6 has osteogenic 
potential. However, BMP6 is crucial in regulating hepcidin and iron metabolism, 
because the main phenotype of the Bmp6 knockout mice is impaired hepcidin 
production and severe iron overload (95,96). Blocking hepcidin transcription by 
targeting the hepatic BMP pathway and more specifically BMP6 may therefore be a 
useful strategy for treating ACD. 
Dorsomorphin is a small molecule inhibitor of BMP receptor Type I kinases that 
was identified in a zebrafish embryo screen. It was also shown to inhibit BMP-, 
HJV-, and IL-6-stimulated hepcidin expression in cultured hepatocytes and block 
iron induced hepcidin mRNA in zebrafish and mice (103). However, dorsomorphin 
(also known as compound C) is a relatively nonselective kinase inhibitor that also 
inhibits AMP kinase (194). A derivative of dorsomorphin, LDN-193189 was shown 
to have improved potency and selectivity as a BMP inhibitor (195) and was able to 
inhibit excessive BMP signaling in vivo (196). We have recently succeeded in using 
LDN-193189 to reverse anemia associated with streptococcal peptidoglycan-
polysaccharide (PG-APS)-induced chronic arthritis in rats (197). Compared to 
mock treatment, LDN-193189 treatment over a period of 4 weeks reduced hepatic 
hepcidin mRNA levels, increased serum iron concentration, increased ferroportin 
expression in splenic macrophages, and importantly, improved hemoglobin levels 
and hematocrit in anemic rats. Consistent with our data, LDN-193189 treatment 
prevented an acute inflammatory anemia induced by turpentine injections in mice 
(198). However, profiling of LDN-193189 against a panel of 123 human kinases 
revealed that it not only blocks the BMP pathway but also potently inhibits VEG-F 
and components of the mitogen-activated protein kinase (MAPK)–extracellular 
signal-regulated protein kinease (ERK) pathway (199). Thus, LDN-193189 is not as 
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specific a BMP inhibitor as initially thought, and caution must be used when 
interpreting results from studies using LDN-193189. 
We have shown that a soluble form of the human hemojuvelin protein linked to the 
constant region of IgG1 (HJV.Fc) can decrease BMP-mediated hepcidin 
expression in vitro. Additionally, HJV.Fc administration into healthy rodents blocked 
SMAD activation, decreased hepcidin expression, mobilized splenic iron stores, 
and increased serum iron levels (200). In collaboration with Ferrumax 
Pharmaceuticals, our recent study in rats with PG-APS-induced ACD indicated that 
pharmacologic inhibition of hepatic BMP signaling with HJV.Fc reduced hepcidin 
mRNA within 24 hr. Longer-term treatment for 4 weeks showed that HJV.Fc 
inhibited phosphorylation of hepatic SMAD 1/5/8, increased splenic ferroportin 
levels and serum iron levels, and rescued the anemia in ACD rats (197). The safety 
and efficacy of HJV.Fc in human patients has not yet been determined. 
Anti-BMP6 monoclonal antibody therapy is another option to specifically block 
BMP6-mediated hepcidin regulation. Administration of anti-BMP mAb in healthy 
mice decreased hepatic hepcidin expression and increased serum iron levels (95). 
In the Hfe transgenic mouse model of excess hepcidin and IDA, anti-BMP6 
administration improved the anemia by lowering hepcidin levels (201). Several 
caveats surround the targeting of BMP6 as a therapeutic strategy. Whether BMP6 
is the most important BMP in the physiologic regulation of hepcidin in humans has 
not yet been shown. Due to high amino acid sequence similarity among the BMP 
family of ligands (202), one technical challenge is to generate antibodies that can 
specifically recognize BMP6 without significant cross-reactivity to other BMPs. 
Finally, the safety of lowering BMP6 in humans is unknown. 
Recently, heparin was implicated in sequestering BMP activity and lowering 
hepcidin expression. Heparin is a highly sulfated glycosaminoglycan that is widely 
used pharmacologically as an anticoagulant. Pretreatment of cultured hepatoma 
cell lines with heparin decreased basal levels of BMP-SMAD signaling and 
inhibited BMP6-mediated hepcidin transcription. Additionally, injection of heparin 
(50 mg/kg) into healthy mice decreased hepatic SMAD phosphorylation and 
reduced hepcidin expression, leading to mobilizing of spleen iron stores and 
increased circulating iron. Moreover, deep vein thrombosis patients treated with 
heparin have decreased serum hepcidin levels and increased serum iron levels 
(203). Whether heparin will become a useful strategy to treat ACD remains to be 
determined, as heparin is known to have significant adverse side effects including 
life-threatening bleeding, heparin-induced thrombocytopenia, hyperkalemia, 
alopecia, and osteoporosis (204). 
Alcohol loading in mice has been shown to decrease hepcidin mRNA and increase 
iron absorption through the intestines (205). The mechanism was recently 
elucidated to involve inhibition of the BMP-SMAD pathway (206). Chronic alcohol 
consumption in humans is associated with excess iron accumulation in the liver, 
and hepcidin may be a contributing factor to the progression of alcoholic liver 
disease (207). The therapeutic potential of using alcohol for the treatment of ACD 
is an interesting strategy that must be tempered by the well-known deleterious side 
effects of excess alcohol use. 
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1.4.9.2.2 IL-6 pathway inhibitors 
 
Inhibitors of the IL-6 pathway have been shown to downregulate hepcidin 
expression and improve anemia of inflammation in Multicentric Castleman's 
Disease, a rare lymphoproliferative disorder marked by excessive production of IL-
6 in the lymph nodes and associated with hypochromic and microcytic anemia. 
Serum hepcidin levels were also elevated in these patients, most likely due to IL-6-
mediated hepcidin synthesis. Most MCD patients (5 out of 6) when treated with the 
anti-IL-6 receptor antibody (anti-IL-6R) Tocilizumab for 6–12 months had lower 
serum hepcidin levels, normalization of hemoglobin levels, and experienced 
beneficial effects on disease symptoms such as reduced fatigue, increased weight, 
and alleviation of fever (208). Another study demonstrated that IV administration of 
anti-IL-6R antibodies ameliorated anemia in a monkey model of collagen-induced 
arthritis. In this model, anti-IL-6R antibody therapy effectively lowered hepcidin 
levels, decreased C-reactive protein (CRP) levels within 1 week, and improved 
hematological parameters over a treatment period of 4 weeks (209). 
Blocking antibodies to the IL-6 ligand also resulted in similar hepcidin lowering 
effects. The anti-IL-6 chimeric monoclonal antibody, Siltuximab, was recently 
demonstrated to increase hemoglobin levels by 2.1 g/dL in an open label, dose 
finding, Phase 1 study in MCD patients (210). The major complication of blockade 
of IL-6 activity appears to be increased risk of infections (211,212). 
In addition to IL-6 ligand/receptor blockade, inhibition of the JAK1/2–STAT3 
signaling cascade can also lower hepcidin expression. The JAK2 inhibitor AG490 
and synthetic peptide inhibitor of STAT3 (PpYLKTK) have been actively studied to 
target cancers with elevated JAK/STAT activity (213-215). AG490 inhibits the 
phosphorylation of STAT3 by JAK2, while the PpYLKTK peptide disrupts pSTAT3 
dimerization, which is required for binding target genes. Faith et al. demonstrated 
that both compounds were able to decrease phosphorylation of STAT3 and 
downregulate IL-6-mediated hepcidin expression in a mouse liver coculture system 
(216). The use of STAT3 inhibitors to modulate hepcidin production in vivo has not 
yet been reported. 
 
1.4.9.2.3 Vitamin D 
 
Vitamin D is a hormone synthesized by the skin on exposure to UV light and 
activated in the kidney. Primarily known for regulating calcium and promoting bone 
health, vitamin D has also been implicated in a wide range of cellular activities 
including differentiation of hematopoietic cells and down regulation of 
proinflammatory cytokines transcripts (217,218). Vitamin D deficiency is associated 
with a higher prevalence of anemia of inflammation in elderly people (219). Vitamin 
D deficiency is also a common occurrence in CKD and hemodialysis patients (220). 
In a recent pilot study, vitamin D supplementation had an erythropoietin (EPO) 
sparing effect in vitamin D deficient hemodialysis patients (221). The results were 
consistent with observations from a retrospective study where vitamin D repletion 
in anemic CKD patients not on hemodialysis correlated with a lowering of EPO 
dose requirements (222). 
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A mechanism for the EPO sparing effects of vitamin D is suggested by recent data 
demonstrating a hepcidin lowering effect of vitamin D. In vitro treatment with 
vitamin D of monocytes isolated from hemodialysis patients downregulated 
hepcidin transcription. Furthermore, oral administration of vitamin D in healthy 
volunteers lowered serum levels of hepcidin by 50% compared to baseline levels 
within 24 hr and persisted for 72 hr (223). Supplementation with vitamin D has also 
been reported to have beneficial effects on increasing erythropoiesis (224) and 
decreasing inflammation (225). These initial results are promising, and a 
randomized controlled study is warranted to determine whether correction of 
vitamin D deficiency can ameliorate ACD. 
 
1.4.9.2.4 Ferroportin Agonists/Stabilizers 
 
Hepcidin excess prevents iron absorption from the diet and blocks iron release 
from body stores by binding to and inducing the degradation of the iron export 
protein ferroportin. In addition to reducing hepcidin production and blocking its 
activity, agents that stabilize ferroportin on the cell surface may be useful for 
correcting the functional iron deficiency in ACD. In a study characterizing the 
molecular mechanism of ferroportin disease with parenchymal iron overload and 
resistance to hepcidin, the thiol form of Cys326 in ferroportin was found to be 
essential in hepcidin–ferroportin interaction (226). In a high-throughput screening 
approach using human embryonic kidney (HEK) cells expressing ferroportin–green 
fluorescent protein (GFP) fusion protein, they discovered thiol modifier compounds 
that prevented ferroportin–hepcidin binding and blocked internalization of 
ferroportin in the presence of excess hepcidin. This screening approach also 
identified molecules, such as cardiac glycosides, which do not interfere with 
hepcidin binding but appear to prevent ferroportin internalization (227). An 
antiferroportin mAb developed by Eli Lilly (Patent Application #20110129480), 
which binds to the extracellular loop of ferroportin, can block the hepcidin–
ferroportin interaction, while maintaining ferroportin function (228). These emerging 
strategies would promote ferroportin activity and allow continuous iron influx, 
potentially preventing iron-restrictive erythropoiesis due to hepcidin excess. The 
safety and efficacy of these approaches in humans have not yet been determined. 
 
1.4.9.3 Conclusions 
 
Recent advances in the iron metabolism field provided valuable insights into the 
molecular pathophysiology of ACD as well as new potential targets for therapy. 
Targeting the hepcidin–ferroportin axis with novel therapeutics that inhibit the 
BMP6–HJV–SMAD and the IL-6–STAT3 pathways for hepcidin production, 
antagonize hepcidin activity, or promote ferroportin function may lead to better 
management of the iron maldistribution and its contribution to the consequent 
anemia of this common but clinically important disorder. 
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2. AIM 
 
In patients with CKD the behaviour of hepcidin and other molecules related to iron 
absorption and transport remains unexplored. 
To investigate these effects and the responses of these components, an animal 
model that represents renal anaemia as seen in patients with CKD is necessary. 
Therefore, we focused on rats with adenine-induced renal failure. 
Adenine treatment in rats has been proposed as an animal model of anemia of 
CKD with high hepcidin levels that mimics the condition in patients (229).  
This model is generated by giving rats a diet supplemented with 0.75% adenine for 
8 weeks, inducing irreversible kidney disease and severe anemia within 4 weeks 
that persists for another 4 weeks. However, this model has a high mortality rate, 
and the hematologic and iron phenotypes have not been fully characterized. 
In this study, we generated a modified adenine diet model that improves the 
survival rate while maintaining irreversible renal failure and anemia. Rats were 
given 0.75% adenine diet for 3 weeks followed by a normal diet for 3 weeks, and 
then characterized for hematological profile, renal parameters, iron status, and 
hepcidin expression. We then investigated whether the small molecule BMP 
inhibitor LDN-193189 was able to inhibit hepatic hepcidin mRNA expression and 
mobilize stored iron into plasma in adenine-treated rats to correct the 
reticuloendothelial cell iron blockade and anemia.  
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3. MATERIALS AND METHODS 
 
3.1 Animals  
 
All animal protocols were approved by the Institutional Animal Care and Use 
Committee at the Massachusetts General Hospital.  
Eight-week-old Wistar male rats (Charles River Labs) were housed in the 
Massachusetts General Hospital rodent facility. Rats were randomized into control 
diet and adenine diet groups each receiving equal amounts of either standard/ 
control (Prolab 5P75 Isopro RMH 3000 diet containing 380 p.p.m. iron) or 0.75% 
adenine supplemented rodent chow (Harlan-Teklad) with similar iron composition.  
To establish the original adenine model, rats in the adenine diet group (n = 12) and 
control diet group (n = 8) were given 0.75% adenine diet and standard rodent chow 
respectively for 6 weeks. Tail vein blood draws were performed weekly and rats 
were sacrificed at week 4 and 6.  
To establish the modified adenine model, rats in the adenine diet group (n = 57) 
were fed on a 0.75% adenine diet for 3 weeks and then fed on control diet over a 
subsequent 5 weeks period. Rats in the control diet group (n = 39) were given a 
control diet through all 8 weeks. Tail vein blood draws were performed every 2 
weeks and rats were sacrificed at time points 1, 2, 4, 6, and 8 weeks.  
For LDN-193189 treatment experiments, 1 week after adenine diet administration, 
8-week-old Wistar male rats in the modified adenine group received either 
intraperitoneal injections of LDN (n = 8) (kindly provided by Charles Hong, 
Vanderbilt University) at 8 mg/ kg daily for 5 wks or the vehicle 2% 2-
hydroxypropyl-B-cyclodextrin (Sigma-Aldrich) in PBS (n = 8) using the same dosing 
regimen. Control diet groups (n = 6) were fed on control diet all six weeks. 
Schematic of experimental design is depicted in Figure 1. Six hours after last 
injection, rats were sacrificed, blood was collected by cardiac puncture and liver 
tissues were harvested for analysis.  
LDN-193189 is a cell permeable small molecule inhibitor of bone morphogenetic 
protein (BMP) type I receptors ALK2 and ALK3 (IC50 = 5 nM and 30 nM 
respectively)
 
(196). LDN-193189 was derived from structure-activity relationship 
studies of Dorsomorphin and functions primarily through prevention of Smad1, 
Smad5, and Smad8 phosphorylation (103,195). LDN-193189 only weakly inhibits 
ALK4, ALK5, and ALK7.  
 
3.2 RNA extraction and quantitative real-time PCR 
 
3.2.1 Preparing RNA 
 
Total RNA was isolated from rat liver tissue using the RNeasy Mini Kit (Qiagen), 
with deoxyribonuclease digestion using the RNase-Free DNase Set (Qiagen) 
according to the manufacturer’s instructions.  
The total RNA had an A260/280 greater than 1.9  
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3.2.2 Converting Total RNA to cDNA 
 
cDNA synthesis was performed using iScript cDNA Synthesis Kit (Bio-Rad) 
according to the manufacturer’s instructions. 
iScript cDNA synthesis kit provides a sensitive and easy-to-use solution for two-
step RT-PCR.  The iScript reverse transcriptase is RNase H+, which provides 
greater sensitivity than RNase H-enzymes in quantitative PCR. iScript is a modified 
MMLV-derived reverse transcriptase, optimized for reliable cDNA synthesis over a 
wide dynamic range of input RNA. The enzyme is provided preblended with RNase 
inhibitor. The unique blend of oligo(dT) and random hexamer primers in the iScript 
reaction mix works exceptionally well with a wide variety of targets. This blend is 
optimized for the production of targets <1kb in length. 
 
3.2.3 Quantitative real-time PCR 
 
Real-time PCR is the ability to monitor the progress of the PCR as it occurs. Data 
is collected throughout the PCR process rather than at the end of the PCR 
process. 
In real-time PCR, reactions are characterized by the point in time during cycling 
when amplification of a target is first detected rather than the amount of target 
accumulated after a fixed number of cycles 
Real-time quantification of mRNA transcripts was performed using 2-step reverse-
transcribed polymerase chain reaction (RT-PCR) using the ABI Prism 7900HT 
Sequence Detection System.  
The two-step method, reverse transcription (RT) and PCR are performed in 
separate reactions, is useful for detecting multiple transcripts from a single cDNA 
template or for storing cDNA aliquots for later use. 
It was performed absolute quantitative real time PCR with a set of standards that is 
generated by making serial dilutions from a sample of known quantity. 
Absolute quantitation (AQ) using standard curve is the process that determines the 
absolute quantity of a single nucleic acid target sequence within an unknown 
sample. AQ assays use a standard curve to calculate the quantity of an unknown 
target sequence. The results of AQ experiments are reported in the same units of 
measure as the standard curve 
Rat Hamp and Hprt transcripts were amplified with specific primers summarized in 
Table 1 and detected using the Power SYBR Green PCR master mix (Applied 
Biosystems) according to the manufacturer’s instructions.  
SYBR Green reagents use SYBR® Green I dye, a double-stranded DNA binding 
dye, to detect PCR products as they accumulate during PCR cycles. 
Samples were analyzed in duplicate or triplicate and expression levels were 
normalized to the housekeeping gene Hprt. 
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Table 1. Primers 
 
Gene Forward (5’-3’) Reverse (5’-3’) 
Hamp  ACAGAAGGCAAGATGGCACT 
 
GAAGTTGGTGTCTCGCTTCC 
 
Crp  GCTTTTGGTCATGAAGACATG 
 
TCACATCAGCGTGGGCATAG 
 
Hprt CTCATGGACTGATTATGGACAGG
AC 
 
GCAGGTCAGCAAAGAACTTA
TAGCC 
 
 
 
3.3 Blood collection 
 
Blood was collected via at tail vein puncture under isofluorane anaesthesia at 
intervals of 1 or 2 weeks during the course of the study. Whole blood was collected 
in BD Microtainer tubes with EDTA (BD Medical No. 365973) for complete blood 
count analysis and reticulocyte hemoglobin analysis at the hematology core facility 
at Children’s Hospital. Blood serum samples were obtained using BD Microtainer 
serum separator tubes (BD Medical No. 365956), according to the manufacturer’s 
instructions and stored at -80 
o
C until time of assessment.  
 
3.4 Hematological analysis 
 
Hemoglobin concentration (Hb), hematocrit (HCT), mean cell volume (MCV), mean 
cell hemoglobin (MCH), red blood cell count (RBC), reticulocyte count (Retic), 
content of hemoglobin in reticulocytes (CHr), mean cell volume of reticulocytes 
(MCVr), platelets (PLT), and white blood cell (WBC) counts were assessed in 
whole blood EDTA using the ADVIA 2120i and analyzed with multispecies software 
using rat settings (ADVIA 2120/2120i).  
The hematocrit (Ht or HCT) or packed cell volume (PCV) or erythrocyte volume 
fraction (EVF) is the volume percentage (%) of red blood cells in blood. 
The mean corpuscular volume, or "mean cell volume" (MCV), is a measure of the 
average red blood cell size. The MCV is calculated by dividing the total volume of 
packed red blood cells (hematocrit) by the total number of red blood cells. The 
resulting number is then multiplied by 10. 
In patients with anemia, it is the MCV measurement that allows classification as 
either a microcytic anemia (MCV below normal range), normocytic anemia (MCV 
within normal range) or macrocytic anemia (MCV above normal range). 
The mean corpuscular hemoglobin, or "mean cell hemoglobin" (MCH), is the 
average mass of hemoglobin per red blood cell in a sample of blood. 
A red blood cell (RBC) count is the number of red blood cells per volume of blood, 
and is reported in either millions in a microliter or millions in a liter of blood. 
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A reticulocyte count is a blood test performed to assess the body's production of 
immature red blood cells (reticulocytes). 
Content of hemoglobin in reticulocytes (CHr) represents the hemoglobin content in 
reticulocytes, the youngest red blood cells (RBC) which transition to mature red 
blood cell in 1 to 2 days. 
 
 
Figure 8. The stages of red blood cell maturation. 
 
The PLT blood test is also known as the platelet blood test or a platelet count. PLT 
in blood test stands for ‘platelet’. PLT testing is done to count how many blood 
platelets there are in our blood.  
White blood cells, or leukocytes play a role in reducing inflammation in the body. A 
high white blood cell count could mean that there is inflammation 
 
3.5 Renal and liver function and electrolyte analyses 
 
Serum samples were analyzed using a DRI-CHEM veterinary chemistry analyzer 
(Heska Corportation, Loveland, CO) at the MGH Clinical Pathology Core for the 
following biochemical parameters: Serum creatinine (Cre), blood urea nitrogen 
(BUN), total protein, albumin (Alb), globulin, glucose (Glu), cholesterol, Alanine 
transaminase (ALT), Alkaline phosphatase (ALP), Gamma glutamyl transpeptidase 
(GGT), total bilirubin (TBIL), sodium (Na), potassium (K), calcium (Ca), inorganic 
phoshorus (P), Choride, and Na/K ratio.   
Creatinine is a non-protein waste product of creatine phosphate metabolism by 
skeletal muscle tissue. Creatinine production is continuous and is proportional to 
muscle mass. Measuring serum creatinine is a useful and inexpensive method of 
evaluating renal dysfunction.  
Creatinine is freely filtered and therefore the serum creatinine level depends on the 
Glomerular Filtration Rate (GFR). Renal dysfunction diminishes the ability to filter 
creatinine and the serum creatinine rises. If the serum creatinine level doubles, the 
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GFR is considered to have been halved. A threefold increase is considered to 
reflect a 75% loss of kidney function. 
The blood urea nitrogen test is a measure of the amount of nitrogen in the blood in 
the form of urea, and a measurement of renal function. Urea is a by-product from 
metabolism of proteins by the liver and is removed from the blood by the kidneys. 
The liver produces urea in the urea cycle as a waste product of the digestion of 
protein. 
The total protein test measures the total amount of two classes of proteins found in 
the fluid portion of your blood: albumin and globulin. 
This test is often done to diagnose nutritional problems, kidney disease or liver 
disease. 
Serum glucose (BG, Glu). 
The liver's ability to produce glucose (gluconeogenesis) is usually the last function 
to be lost in the setting of fulminant liver failure. 
A complete cholesterol test — also called a lipid panel or lipid profile — is a blood 
test that can measure the amount of cholesterol and triglycerides in the blood. A 
cholesterol test can help determine risk of atherosclerosis, the buildup of plaques in 
arteries that can lead to narrowed or blocked arteries. 
Alanine transaminase or ALT is a transaminase enzyme. 
ALT is found in serum and in various bodily tissues, but is most commonly 
associated with the liver. It catalyzes the two parts of the alanine cycle. 
It is measured clinically as a part of a diagnostic evaluation of hepatocellular injury, 
to determine liver health. 
The alkaline phosphatase (ALP) test measures the amount of the enzyme ALP in 
the blood. The test is used to help detect liver disease or bone disorders. 
Gamma-glutamyl transpeptidase (GGT) is a test to measure the amount of the 
enzyme GGT in the blood. 
This test is used to detect diseases of the liver or bile duct disorders and bone 
disease. 
Bilirubin is a breakdown product of heme (a part of hemoglobin in red blood cells). 
The liver is responsible for clearing the blood of bilirubin. Bilirubin is measured to 
diagnose and/or monitor liver diseases. 
A sodium test checks how much sodium (an electrolyte and a mineral) is in the 
blood. Sodium is both an electrolyte and mineral. It helps keep the water (the 
amount of fluid inside and outside the body's cells) and electrolyte balance of the 
body. Sodium is also important in how nerves and muscles work. 
Electrolytes test detects a problem with the body's fluid and electrolyte balance. 
 
3.6 Serum iron measurements 
 
Serum was collected and analyzed for iron concentration and unsaturated iron-
binding capacity. Serum iron and unsaturated iron-binding capacity (UIBC) were 
measured by colorimetric assay using the Iron/UIBC kit (Thermo Electron Corp.). 
Total iron-binding capacity (TIBC) was calculated as the sum of serum iron and 
UIBC measurements, and transferring saturation percentage was calculated as 
serum iron / TIBC × 100. 
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3.7 Tissue iron measurement 
 
Immediately after harvest, livers and spleen were sectioned into 2mm cubes and 
weighed. Quantitative measurement of nonheme iron was performed according to 
the method of Torrence and Bothwell [41]. Results are reported as micrograms 
iron/gram wet weight tissue. 
 
3.8 EPO ELISA 
 
Serum erythropoietin concentrations were measured using a mouse/rat EPO 
serum/plasma singleplex immunoassay kit (Meso Scale Discovery, Gaithersburg, 
MD). Analysis was performed per manufacturer’s protocol  
 
3.9 Statistics 
 
Results were expressed as mean ± SEM values. A two-tailed Student’s t-test with 
P < 0.05 was used to determine statistical significance. 
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4. RESULTS 
  
4.1 Characterization of a modified adenine model of anemia of 
CKD 
 
4.1.1 A modified adenine model improves survival and maintains 
irreversible renal failure 
 
Treatment of rats with a diet supplemented with 0.75% adenine for 8 weeks has 
previously been proposed as an animal model of anemia of CKD with high hepcidin 
levels that mimics the condition in patients (229,230). We therefore tested this 
model in our laboratory to perform a more detailed characterization of the anemia 
phenotype, with the ultimate aim to test hepcidin lowering agents as a new strategy 
to treat disordered iron homeostasis and anemia of CKD. We found that treatment 
with a 0.75% adenine diet continuously lead to a very high morality rate of 66.7% 
(4/6) by 6 weeks. Although mortality was not mentioned in the paper by Yokozawa 
et al. (229) a similarly high mortality rate has been seen by other groups (231).  
We therefore developed a modified adenine treatment model with the aim to 
maintain irreversible renal failure and anemia, but to improve survival. It has 
previously been reported that treatment with 0.75% adenine diet for 4 weeks 
followed by a normal diet for 4 weeks maintained irreversible renal failure and 
anemia with improved survival to 81. Administration of 0.75% adenine diet for 2 
weeks followed by a normal diet for 4 weeks improved survival to 100%, but 
resulted in reversible renal failure and only a mild anemia (231) To try to improve 
survival further, but maintain irreversible renal failure and anemia, we tested the 
effects of 0.75% adenine diet treatment for 3 weeks followed by a control diet for 5 
weeks -“Modified Adenine Diet”. Survival, weights and renal function parameters 
were compared to the continuous adenine treatment for 6 weeks –“Original 
Adenine Diet” and rats maintained on a control diet for 8 weeks -“Control Diet” 
(Figure 9). 
Control diet rats had 100% survival and gained an average of 9% in weight every 
week up to 86% increase above the initial weight. Modified adenine diet rats at the 
end of the 3 week period had an 13% loss in weight compared to the pretreatment 
value. However, a change to control diet for the following 3 weeks allowed a steady 
weight gain to 53% above the initial weight by the end of the experiment (Figure 
9A). In contrast, rats receiving continuous adenine diet for 6 weeks continued to 
lose weight, down to 51% of initial weight by the end of the experiment (Figure 9A). 
Rats receiving the modified adenine treatment greatly improved their survival rate 
to 96.4% (54/56 survived) (Figure 9B), compared to rats receiving continuous 
adenine diet for 6 weeks which had a 33.3% survival rate (2/6 survived) (Figure 
9B).   
Modified adenine diet rats had a significant increase in creatinine (Cre) and blood 
urea nitrogen (BUN) by week 1 that remained increased at week 6 despite a 
change to normal diet after week 3, indicating irreversible deterioration of kidney 
function with just 3 weeks of adenine-diet treatment (Figure 9C-D). Indeed, kidneys 
from these rats appeared pale and enlarged at the time of sacrifice at 6 weeks, 
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similar to the kidneys from rats receiving continuous adenine diet for 6 weeks. This 
increase in Cre and BUN persisted even to 8 weeks (Figure 9C-D). We observed a 
small increase in serum potassium in adenine treated rats, but did not observe any 
other significant electrolyte imbalance in this model compared to the control diet 
group (Table 2). We also did not observe any changes in albumin, bilirubin, ALT 
and ALP, indicating that the adenine treatment did not contribute to hepatic injury 
or toxicity (Table 2).   
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Figure 9. Increased survival and maintenance of irreversible renal failure in 
Modified Adenine Model compared to the Original Adenine Model  
 
A) Body weights (grams) for rats on control diet, adenine diet for 3 weeks followed 
by 5 weeks of control diet -modified adenine diet, and continuous adenine diet - 
original adenine diet were monitored weekly for a duration of 8 weeks. Rats on 
control diet (open diamonds) increased in weight each week. In contrast, rats on 
original adenine diet (open triangles) steadily lost weight throughout the 
experimental period. Rats on the modified adenine diet (open squares) lost weight 
in the first 3 weeks while on the adenine diet, however when control diet was 
introduced, their weights steadily increased almost to the weights of their control 
diet only counterparts by the end of 8 weeks. For each group, significant changes 
are shown as (** P<0.01, * P=0.02) in comparison to the control diet.  
B) Survival rates for control diet, modified adenine diet and original adenine diet 
were plotted as percent survival. All rats on the control diet (open diamonds) 
survived the 8 week experimental period, rats on the original adenine diet (open 
triangles) had a 30% survival rate at week 6 while rats on the modified adenine diet 
(open squares) had a 96.4% survival rate at 8 weeks. The surviving rats on the 
original adenine diet were in such poor health condition that they were sacrificed at 
week 6.  
C) Serum creatinine (CRE) and D) serum blood urea nitrogen (BUN) were 
collected from all groups to measure renal function. Rats receiving control diet had 
low CRE and BUN levels indicating normal functioning kidneys, while rats on the 
original adenine diet increased CRE and BUN levels continuously indicating severe 
renal failure. Rats on the modified adenine diet had a steady increase in CRE and 
BUN until 3 weeks and maintained the increase throughout the experimental 
period, indicating irreversible renal failure. 
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Table 2. Renal and Liver biochemical parameters in Adenine rats at 6 weeks  
 
  Units  Control Diet (N=4) Adenine Diet (N=8) 
BUN mg/dl 21.70 + 1.8 66.36 + 19.45* 
Creatinine mg/dl 0.25 + 0.10 0.94 + 0.29* 
Phosphorus mg/dl 7.28 + 0.57 7.53 + 1.10 
Calcium mg/dl 9.83 + 0.92  11.13 + 0.18 
Total Protein g/dl 5.10 + 0.47 4.98 + 0.21 
Albumin g/dl 3.40 + 0.24 3.48 + 0.17 
Globulin g/dl 1.70 + 0.27 1.50 + 0.11 
Glucose mg/dl 189.00 + 25.73 166.00 + 10.10 
Cholesterol mg/dl 63.25 + 9.64 94.13 + 12.96* 
ALT (GPT) U/l 28.50 + 1.29 33.38 + 7.01 
ALP U/l 196.00 + 32.16 236.00 + 28.08 
GGT U/l 11.67 + 1.53 10.25 + 0.50 
Total Bilirubin mg/dl 0.28 + 0.10 0.38 + 0.16 
Sodium mEq/l 134.50 + 6.45 141.50 + 2.39 
Potassium mEq/l 4.38 + 0.25 5.08 + 0.65* 
Chloride mEq/l 95.25 + 4.92  101.88 + 3.09 
Na/K Ratio   30.75 + 1.50 28.38 + 4.07 
 
*p-values <0.01 
 
 
4.1.2 A modified adenine model exhibits irreversible anemia, 
hypoferremia,  reticuloendothelial cell iron blockade and hepcidin 
excess. 
 
The modified adenine diet rats developed anemia associated with renal failure at 
week 4 with hemoglobin (Hb) and hematocrit (HCT) levels at levels at 11g/dL and 
35% compared to control diet rats with normal hemoglobin (Hb) and HCT levels at 
15g/dL and 50% (Fig 10A and 11A). The anemia was long lasting, with Hb and 
HCT levels remaining at 10g/dL and 30% at week 6 and 9g/dL and 25% 
respectively at week 8 (Fig 10A and 11A). The decrease in HCT was due largely to 
a drastic reduction in reticulocytes (retic) after week 1 on the adenine diet, which 
remained decreased until week 5, at which time it approached the levels in control 
animals, but remained inappropriately low relative to the degree of anemia (Figure 
10B). Similarly, the mean corpuscular volume of reticulocytes (MCVr) was also 
decreased (Figure 10C). There was also a marked decrease in iron incorporation 
into reticulocytes as measured by content of hemoglobin in reticulocytes (CHr) from 
weeks 1-3 in the adenine-treated rats compared to controls (Figure 10D). Effects 
on other complete blood count parameters are shown in Figure 11. These blood 
parameters indicate that the adenine-treated rats developed anemia within 4 
weeks, characterized by a decreased production of red blood cells, and a clear lack 
of iron incorporation into the reticulocytes up to week 3.  
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Figure 10. Characterization of Anemia in Modified Adenine Model  
A) Rats on the modified adenine diet (open squares) are anemic at week 4, with 
hemoglobin levels at 11 g/dL compared to 15 g/dL in control diet rats (open 
diamonds). The anemia associated with renal failure continues to week 8. B) 
Reticulocyte analysis in modified adenine diet rats show a significant reduction in 
reticulocyte count after 1 week on the adenine diet and remained significantly 
decreased until week 5, contributing to low hematocrit (HCT, Supplemental Figure 
1A). C) Similarly, due to the decrease in reticulocyte number, the mean corpuscular 
volume of reticulocytes (MCVr) is decreased in the first 1-3 weeks on adenine diet. 
D) Modified adenine diet rats have decreased iron incorporation into the 
reticulocytes within this first 1-3 weeks as evidenced by lowered content of 
hemoglobin in reticulocytes (CHr) compared to control, indicating iron deficiency. 
Differences between groups were tested by unpaired t tests. ** P<0.01, *P=0.01, 
^P=0.03 compared to control rats, comparisons were made for each time point. 
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Figure 11. Complete blood count parameters for modified adenine diet rats 
A) Rats on the modified adenine diet (open squares) are anemic and display low 
hematocrit (HCT) compared to control diet rats (open diamonds) at week 4. The 
anemia associated with renal failure continues to week 8. B) Adenine diet rats also 
have low mean corpuscular volume (MCV) and C) mean corpuscular hemoglobin 
(MCH) from week 1-4, with no changes in D) mean corpuscular hemoglobin 
content (MCHC) until week 8. E) White blood cell counts are significantly increased 
in adenine diet rats from week 1-6 while F) red blood cell counts are decreased in 
adenine diet rats from week 4-8 compared to controls. G) Platelet counts are 
significantly increased in adenine diet rats from week 2-4 and returned to control 
levels from week 5-8. Differences between groups were tested by unpaired t tests. 
^P=0.01, *** P<0.01, **P=0.02, *P=0.03, compared to control rats, comparisons 
were made for each time point. 
 
 
Consistent with the decreased iron content in reticulocytes, the modified adenine 
diet rats exhibited reduced serum iron and transferrin saturation from weeks 1-3 
compared with control rats (Figure 12A-B). Adenine treated rats also exhibited iron 
retention in the spleen throughout the entire experimental period (Figure 12C). 
These data are consistent with a reticuloendothelial cell iron blockade that is 
characteristic of anemia of chronic kidney disease. Interestingly, by weeks 5-6, the 
serum iron levels and transferrin saturation, MCVr, and CHr increased to surpass 
the level in control animals, suggesting that there was some improvement in iron 
availability after week 3 in this model. 
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Figure 12. Decreased serum iron concentration and increasing spleen iron content 
within 3 weeks on Adenine diet  
A) Rats receiving adenine diet (open squares) had decreased levels of serum iron 
and B) lowered transferrin saturation (Tfsat) during the first 3 weeks compared to 
those on control diet (open diamonds). However, when adenine rats received 
control diet after week 3, the serum iron levels and Tfsat returned to control levels. 
C) The reduction of available circulating iron is due to iron accumulation in the 
splenic reticuloendothelial macrophages as adenine diet rats have significantly 
increased values of spleen iron content compared to control rats throughout the 8 
week experimental period. Differences between groups were tested by unpaired t 
tests. ** P<0.01, *P=0.05, ^P=0.03, compared to control rats, comparisons were 
made for each time point. 
 
Hepcidin excess has been implicated in causing the functional iron deficiency and 
reticuloendothelial cell iron blockade often seen in patients with anemia of CKD.  
We therefore measured the levels of hepatic hepcidin mRNA in the adenine-treated 
rats compared to control diet rats. Hepcidin expression in the liver was increased 
by 3-fold within 1 week of adenine treatment (Figure 13A). Hepcidin expression 
remained high at 2 and 4 weeks in the adenine-treated rats, but then decreased 
compared to control animals at week 6 to 8. Presumably, the decrease in hepcidin 
at the later time points is a response to the anemia, which is a potent suppressor of 
hepcidin expression. In fact, the hepcidin levels in weeks 6 to 8 may still be 
inappropriately high relative to the degree of anemia, since mice with a similar 
degree of anemia have about 10-fold lower hepcidin levels compared with 
nonanemic mice (ref). The decrease in hepcidin mRNA levels at later time points 
corresponds to increased iron availability for erythropoiesis, manifest by increased 
serum iron, transferrin saturation, and CHr (Figure 12A, B, Figure 10D). These data 
suggest that hepcidin excess may be at least in part responsible for the 
reticuloendothelial cell iron blockade and anemia of this modified adenine model. 
Hepcidin excess in CKD has been attributed to reduced renal clearance and/or 
stimulation by inflammation. As an indicator of an inflammatory response in the 
liver, we assessed if C-reactive protein (CRP) mRNA levels in liver were increased 
in adenine-treated rats. CRP mRNA levels in the livers of adenine rats were slightly 
but significantly increased at 2 weeks of adenine treatment compared to control 
(Figure 13B).   
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Figure 13. Hepatic hepcidin mRNA expression is increased and is correlated with 
increased hepatic CRP mRNA expression in Modified Adenine Model  
A) Rats on modified adenine diet (open squares) increased hepcidin mRNA 
expression by 3 fold at week 1 and remained significantly increased until week 4 
compared to control diet rats (open diamonds). B) C-reactive protein, CRP, a 
marker of inflammation was increased at week 2. Results are shown as fold 
change of HAMP/HPRT ratio or CRP/HPRT where expression of hypoxanthine 
phosphoribosyltransferase, HPRT, served as an internal control. Differences 
between groups were tested by unpaired t tests. ** P<0.01, *P=0.02, ^P=0.03, 
compared to control rats, comparisons were made for each time point 
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4.2 Treatment with LDN-193189 lowers hepcidin, mobilizes 
spleen iron stores, increases serum iron and increases iron 
incorporation into reticulocytes, but does not improve anemia in 
a modified adenine model. 
 
Since the modified adenine-induced renal failure model is a high hepcidin model 
reflective of the reticuloendothelial cell iron blockade and anemia associated with 
CKD patients, we investigated whether hepcidin inhibition, by pharmacologic 
treatment with a small molecule BMP signaling inhibitor LDN-193189 (LDN), would 
mobilize stored iron from the reticuloendothelial macrophages, increase iron 
availability for erythropoiesis, and correct the anemia. We treated rats at 1 week 
post adenine diet administration (Figure 14) since hepcidin was maximally 
increased. Furthermore, we observed reduced serum iron, spleen iron 
sequestration, and reduced iron incorporation into reticulocytes suggestive of 
functional iron deficiency at this time point.  
 
 
 
Figure 14. Schematic of LDN-193189 treatment strategy in modified adenine-
induced renal failure model. 8-week old Wistar male rats were given either control 
diet (open bars) for duration of 6 weeks or 0.75% adenine supplemented diet 
(black bars) for 3 weeks followed by control diet (open bars) for another 3 weeks. 
The adenine diet group was further divided into a mock treatment arm or treatment 
arm receiving daily injections of either cyclodextrin or LDN-193189 at a dose of 
8mg/kg, respectively, starting at week 1. Tail-vein blood draws (indicated by 
triangles) were performed at week 0, 2, 4, and 5 for all groups. Animals were 
sacrificed (S) at week 6 with blood collection by cardiac puncture, followed by 
harvesting of the liver for analysis of hepatic hepcidin mRNA expression. 
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After 5 weeks of treatment with LDN-193189, hepatic hepcidin expression was 
dramatically downregulated compared to rats treated with vehicle only and rats on 
a control diet (Figure 15).   
 
Figure 15. Effective inhibition of hepcidin expression in LDN treated Adenine rats at 
6 weeks. Hepcidin mRNA expression relative to the housekeeping gene HPRT was 
determined in livers of control and adenine diet rats which were daily treated with 
either a single injection of vehicle or LDN-193189 (8mg/kg) from week 1 to week 6 
and sacrificed 6 hours after last injection. LDN treatment significantly reduced liver 
hepcidin mRNA expression in the adenine diet rats (dotted bar) compared to 
adenine rats receiving cyclodextrin vehicle treatment (black bar). Hepcidin mRNA 
levels in adenine rats (black bar) are low compared to control diet rats (white bar) 
at week 6. Differences between groups were tested by unpaired t tests. ** P<0.01, 
compared to adenine diet rats receiving vehicle control and *P=0.02, compared to 
control rats. 
 
The effect of hepcidin inhibition was evident by week 3 and week 5, where serum 
iron concentrations and transferrin saturation in LDN treated adenine rats were 
significantly increased compared to vehicle-treated adenine rats (Fig. 16A and 
16B) This surge in circulating levels of serum iron was at least in part due to 
release of stored iron from the reticuloendothelial macrophages in the spleen since 
LDN treated rats had significantly less iron content in the spleen compared to their 
vehicle treated counterparts, with iron content levels similar to the control diet 
group (Figure 16C). Importantly, this surge of iron availability correlated with an 
increase in hemoglobin content of reticulocytes (Figure 17A) and mean corpuscular 
volume of reticulocytes (Figure 17B) at week 3 and week 5, suggesting that the 
iron was efficiently being incorporated into reticulocytes. The overall mean cell 
volume (MCV) and mean cell hemoglobin (MCH) were also significantly increased 
by week 6 (Fig. 17E-F) However, LDN treatment alone caused only a trend 
towards increased reticulocyte count, and did not correct Hb levels in the adenine 
rats (Figure 17C-D).  
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Figure 16. LDN treated Adenine rats show mobilization of stored iron into plasma  
A) LDN treatment of adenine rats (closed squares) resulted in a significant increase 
of serum iron levels and B) transferrin saturation (Tfsat) by week 3 and 5 compared 
with vehicle treated controls (open squares). C) The increase in available serum 
iron is due to iron mobilization from spleen with significantly decreased values of 
spleen iron content in adenine rats treated with LDN (dotted bar) compared to 
vechicle treated control (black bar). Differences between groups were tested by 
unpaired t tests. ** P<0.01, *P=0.05, compared to adenine diet vehicle control rats, 
comparisons were made for each time point. 
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Figure 17. LDN treated Adenine rats show significant increase of hemoglobin 
incorporation into reticulocytes and increased mean cell volume of reticulocytes 
which ultimately increased mean corpuscular volume and mean cell hemoglobin at 
week 6, but LDN treatment did not increase overall Hb levels.  
A) The reticulocyte analysis shows a significant increase of hemoglobin 
incorporation into reticulocytes (CHr) and B) increased mean cell volume of 
reticulocytes (MCVr) in LDN treated rats (closed squares) at week 3 and week 5. 
C) Reticulocyte counts recovered spontaneously due to switching of control diet at 
week 3 and LDN treatment had no additional effect of increasing retic count. D) 
LDN treatment did not increase overall hemoglobin levels (Hb) but did increase 
mean corpuscular volume (MCV) and mean cell hemoglobin (MCH) by the end of 
the experimental period at week 6. Differences between groups were tested by 
unpaired t tests. ** P<0.01, *P=0.02, ^P= 0.05, #P=0.04 compared to adenine diet 
vehicle control rats, comparisons were made for each time point. 
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4.3 Adenine induces an acute decrease in circulating 
erythropoietin to undetectable levels. 
  
In an effort to understand the contribution of erythropoietin (232) deficiency to the 
anemia of the adenine-induced renal failure model, we examined the serum EPO 
levels in the adenine-treated rats at week 1 and at week 6 in the absence and 
presence of LDN treatment. Serum EPO levels were well below the limit of 
detection after 1 week of adenine-treatment compared to controls (Figure 18). This 
drop in EPO levels is directly correlated to the precipitous drop in reticulocyte count 
at week 1 of adenine-treatment (Figure 10B). However, at week 6, the EPO levels 
in adenine-treated rats returned to a similar level as rats on a control diet, 
comparable to what has been reported in human patients with CKD. Such “normal” 
EPO levels in CKD patients with anemia are suggested to be inappropriately low 
relative to the degree of anemia, since human patients with anemia in the absence 
of kidney disease typically have EPO levels about 10-100-fold higher than baseline 
(ref). Interestingly, there was a trend towards an increase in EPO levels in LDN 
treated adenine rats, albeit not significant.    
 
Figure 18. Serum EPO levels in Modified Adenine Model at week 1 and effect of 
LDN treatment on EPO levels at week 6.   A) Serum EPO levels are below the limit 
of detection in adenine diet rats at week 1, these values correlate with the 
significant reduction of reticulocyte number (Figure 3B). At week 6, adenine diet 
rats display relative EPO deficiency due to anemia as evidenced by similar levels 
of EPO in both adenine diet rats and control rats. LDN treatment of adenine rats 
induced an increase in EPO levels but is not significant. Differences between 
groups were tested by unpaired t tests. ** P<0.01, compared to control rats. 
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5. DISCUSSION 
 
We developed an animal model of anemia of CKD with hepcidin excess and 
demonstrated for the first time that pharmacologic intervention to lower hepcidin 
expression can correct the functional iron deficiency in anemia of CKD.  
The adenine-induced kidney disease model in rats was first published in 1986 by 
Yokozawa et al. (229,233). Dietary supplementation with adenine is thought to 
induce kidney disaese in rats primarily due to obstruction of renal tubules by 2,8-
dihydroxyadenine crystals (231). The adenine model is often used to study anemia 
associated with CKD because it reflects the severe anemia seen in patients better 
compared to the other widely used 5/6 nephrectomy CKD model that is associated 
with a more mild anemia without alterations in serum iron parameters (234-236). 
The adenine model was also recently proposed to exhibit elevated hepcidin levels 
(237), similar to what has been demonstrated in human patients with CKD. 
However, a full characterization of the hematologic and,iron parameters in the 
adenine model has been limited (230,231,238) and the mortality rate in the 
Yokozawa model is prohibitively high (67%) both in ours and others hands. We 
therefore developed a modified adenine model by giving a diet supplemented with 
0.75% adenine for 3 weeks followed by adenine free normal diet for another 3 
weeks, which we demonstrated had a higher survival rate than the Yokozawa 
model and other previously published models, while maintaining irreversible renal 
failure and anemia. Moreover, we demonstrated that adenine-treated rats have 
increased hepatic hepcidin levels, decreased serum iron concentration, increased 
spleen iron content, low hemoglobin levels and inappropriately low EPO levels 
relative to the degree of anemia, reflective to some extent of the clinical condition in 
patients with anemia of CKD.  
Current management of anemia of CKD are co-administration of ESAs and 
supplemental iron (239-241). However, ESA therapies have been associated with 
increased morbidity and mortality in several recent clinical trials. The Correction of 
Hemoglobin in Outcomes and Renal Insufficiency (CHOIR) and Trial to Reduce 
cardiovascular Events with Aranesp Therapy (TREAT) studies revealed that CKD 
patients who received ESA doses to achieve target hemoglobin levels >13g/dL had 
a higher incidence of cardiovascular events, stroke, progression of cancer and 
death (242,243).  In addition, not all patients respond to ESAs or iron therapy 
adequately, and these therapies do not fully address the underlying 
pathophysiologic mechanisms of this disease. For example, CKD patients, 
particularly patients on hemodialysis, have excess levels of the main iron 
regulatory hormone hepcidin, and hepcidin excess has been proposed to 
contribute to the anemia of CKD by limiting iron availability for erythropoiesis. 
Providing supraphysiologic iron to these patients would worsen the iron restriction 
and functional iron deficiency in these patients since intravenous iron can potently 
stimulate hepcidin production by threefold in CKD patients (24).   
Therefore, we tested whether pharmacologic intervention to lower hepcidin 
expression can correct the functional iron deficiency that contributes to the anemia 
in our model of anemia of CKD. We showed here that the small molecule inhibitor 
LDN-193189 lowered endogenous hepatic hepcidin production, mobilized stored 
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iron into plasma and increased circulating serum iron levels within 2 and 4 weeks 
of LDN treatment. The available iron was efficiently incorporated into hemoglobin in 
reticulocytes, the precursors to mature red blood cells. Previous studies in patients 
with CKD have suggested that absolute iron deficiency can contribute to anemia 
and ESA hyporesponsiveness, and that iron therapy can raise hemoglobin levels 
and reduce ESA requirements (161,244). Our data provide the first proof of 
concept evidence that pharmacologic hepcidin lowering strategies can improve iron 
availability for erythropoiesis in an animal model of anemia of CKD. By improving 
iron absorption from the diet and iron mobilization from the patient’s own body 
stores, hepcidin lowering strategies could provide an alternative and/or adjunctive 
therapy to IV iron and ESAs that can minimize the potential adverse consequences 
of high doses of ESAs and repeated IV iron administration. This would be a 
particularly attractive option for patients with low serum transferrin saturation and 
high serum ferritin, for whom current guidelines are unclear how to manage. 
Despite an increase in serum iron and improvement in iron incorporation into red 
blood cells, treatment with LDN-193189 alone did not prevent the anemia 
progression in our model. This contrasts with studies in two other models of 
anemia of chronic disease in the absence of kidney disease, a group A 
streptococcal peptidoglycan-polysaccharide (PG-APS) model of relapsing arthritis 
or chronic turpentine treatment, where that treatment with LDN193189 alone was 
able to ameliorate anemia. In another anemia of chronic disease model induced by 
injection of heat-killed Brucella abortus, treatment with a blocking hepcidin antibody 
alone was not able to prevent anemia development, but did improve anemia when 
co-administered with ESAs compared to ESA administration alone. One 
explanation for the difference in our model compared to other animal models is that 
erythropoietin deficiency may play a more prominent role in anemia in CKD 
compared with other chronic diseases. Our data suggests that hepcidin excess and 
restricted iron availability are not limiting factors for the development of anemia in 
the modified adenine model. Future studies will be needed to test whether co-
adminstration of hepcidin lowering agents such as LDN-193189 will be useful as 
adjunctive therapy with ESAs to improve hemoglobin levels while reducing ESA 
dose in models of anemia of chronic kidney disease.  
One limitation of the modified adenine model is that EPO levels dramatically fell 
and were undetectable at 1 week, corresponding to the precipitous drop in 
reticulocyte counts. Endogenous serum EPO levels during the early weeks of the 
adenine-induced renal failure model have not been reported. This finding was 
surprising as published reports in CKD patients demonstrate relative EPO 
deficiency in renal anemia compared to healthy controls rather than an absolute 
absence of EPO. Therefore, this result is not reflective of the EPO levels measured 
in anemic CKD patients, which are generally in the normal range or slightly 
increased, albeit inappropriately low relative to the degree of anemia (245). It 
seems likely that the severe EPO deficiency characteristic of the early phase of this 
model was a limiting factor in the correction of anemia with LDN-193189 alone. 
Another limitation of this model is that hepcidin levels fell and serum iron levels 
rose on their own after 4 weeks, thereby limiting the therapeutic window for 
hepcidin lowering agents in this model. The mechanism of hepcidin excess in 
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patients with CKD is thought to be due to reduced renal clearance and stimulation 
by inflammatory cytokines (237). We were unable to measure circulating levels of 
bioactive hepcidin in this model because there is no currently available assay for 
this in rats. If reduced renal clearance were present in this model, circulating 
bioactive hepcidin levels could be even higher than reflected by the liver mRNA 
levels. However, it seems unlikely that hepcidin excess was present after 4 weeks, 
given the rise in serum iron levels above baseline. Future studies will be needed to 
develop animal models of anemia of chronic kidney disease that more accurately 
reflect the characteristics of human patients with this disease to help further test 
alternative treatment strategies for this disease.  
 In summary, we have provided the first experimental evidence that 
lowering hepcidin can increase iron availability for incorporation into red blood cells 
in an animal model of anemia of CKD. By correcting hepcidin excess to allow 
normal dietary iron absorption and mobilization of iron from body stores, such 
strategies could be anticipated to reduce the requirement for intravenous iron 
therapy and high dose ESAs to improve safety and efficacy of anemia 
management in CKD patients. 
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